CA2285490C - Composition for improvement of cellular nutrition and mitochondrial energetics - Google Patents
Composition for improvement of cellular nutrition and mitochondrial energetics Download PDFInfo
- Publication number
- CA2285490C CA2285490C CA002285490A CA2285490A CA2285490C CA 2285490 C CA2285490 C CA 2285490C CA 002285490 A CA002285490 A CA 002285490A CA 2285490 A CA2285490 A CA 2285490A CA 2285490 C CA2285490 C CA 2285490C
- Authority
- CA
- Canada
- Prior art keywords
- carnitine
- taurine
- patients
- heart
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000016709 nutrition Nutrition 0.000 title abstract description 17
- 230000002438 mitochondrial effect Effects 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title description 12
- 230000035764 nutrition Effects 0.000 title description 10
- 230000001413 cellular effect Effects 0.000 title description 9
- 230000006872 improvement Effects 0.000 title description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 130
- 229960003080 taurine Drugs 0.000 claims abstract description 65
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 49
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 46
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 41
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 19
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 15
- 229940035936 ubiquinone Drugs 0.000 claims description 24
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 17
- 241000282412 Homo Species 0.000 claims description 13
- 208000019622 heart disease Diseases 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 13
- 230000032683 aging Effects 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 241000282326 Felis catus Species 0.000 claims description 7
- 230000006866 deterioration Effects 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000037147 athletic performance Effects 0.000 claims description 4
- 230000002232 neuromuscular Effects 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 abstract description 64
- 229960004203 carnitine Drugs 0.000 abstract description 45
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract description 38
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 abstract description 28
- 235000019157 thiamine Nutrition 0.000 abstract description 26
- 239000011721 thiamine Substances 0.000 abstract description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 23
- 235000018102 proteins Nutrition 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 229960003624 creatine Drugs 0.000 abstract description 19
- 239000006046 creatine Substances 0.000 abstract description 19
- 230000009469 supplementation Effects 0.000 abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 15
- 230000005856 abnormality Effects 0.000 abstract description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 13
- 235000018417 cysteine Nutrition 0.000 abstract description 13
- 235000019165 vitamin E Nutrition 0.000 abstract description 13
- 239000011709 vitamin E Substances 0.000 abstract description 13
- 229930003427 Vitamin E Natural products 0.000 abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 12
- 229940046009 vitamin E Drugs 0.000 abstract description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 6
- 235000011649 selenium Nutrition 0.000 abstract description 6
- 229910052711 selenium Inorganic materials 0.000 abstract description 6
- 239000011669 selenium Substances 0.000 abstract description 6
- 238000012937 correction Methods 0.000 abstract description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract description 3
- 229960001009 acetylcarnitine Drugs 0.000 abstract description 3
- 229960002433 cysteine Drugs 0.000 abstract description 2
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 description 43
- 210000002216 heart Anatomy 0.000 description 40
- 230000001965 increasing effect Effects 0.000 description 36
- 230000000747 cardiac effect Effects 0.000 description 26
- 230000002107 myocardial effect Effects 0.000 description 25
- 229960003495 thiamine Drugs 0.000 description 24
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 235000015097 nutrients Nutrition 0.000 description 23
- 210000002027 skeletal muscle Anatomy 0.000 description 23
- 239000013589 supplement Substances 0.000 description 23
- 230000036542 oxidative stress Effects 0.000 description 22
- 230000004064 dysfunction Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000004165 myocardium Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 241000699800 Cricetinae Species 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 208000002894 beriberi Diseases 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 208000005428 Thiamine Deficiency Diseases 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 208000002720 Malnutrition Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 210000000107 myocyte Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 208000020446 Cardiac disease Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 6
- 229960003883 furosemide Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000006371 metabolic abnormality Effects 0.000 description 6
- 230000004220 muscle function Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000037323 metabolic rate Effects 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000002715 bioenergetic effect Effects 0.000 description 4
- 230000001756 cardiomyopathic effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- -1 that of carnitine Chemical compound 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- 206010058892 Carnitine deficiency Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000006286 nutrient intake Nutrition 0.000 description 3
- 235000003715 nutritional status Nutrition 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020674 Hypermetabolism Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000008425 Protein deficiency Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001201 calcium accumulation Effects 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003617 peroxidasic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000004482 ATP Translocases Mitochondrial ADP Human genes 0.000 description 1
- 108010017236 ATP Translocases Mitochondrial ADP Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 1
- 101710119049 Glutathione peroxidase 3 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010026865 Mass Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010074253 Phosphatidyl-N-Methylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 108010030678 Phosphatidylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- 102100028873 Sodium- and chloride-dependent taurine transporter Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011686 genetic mapping animal model Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 108010017629 taurine transporter Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940004177 thiamine 25 mg Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
This invention provides a dietary supplement comprising L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-I-Carnitine), Coenzyme Q10 and Taurine for the correction of the abnormality in mitochondrial energetics in cardiac failure and certain other diseases. A high protein nutritional feeding supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin in may be added.
Description
COMPOSITION FOR IMPROVEMENT OF CELLULAR NUTRITION AND
MITOCHONDRIAL ENERGETICS
BACKGROUND
Oman Failure and Nutrition There are four critical organ systems that are especially likely to fail in aging and critical illness.
They are the cardiovascular, central nervous, musculoskeletal and immune systems.
Relationship of malnutrition to mitochondria) function.
Protein-calorie malnutrition contributes to both skeletal and cardiac' muscle dysfunction in patients with cardiac failure. Muscle is composed of water, minerals, nitrogen and glycogenz,3 Feeding wasted individuals results in a gain of the multiple elements in lean tissue4 including potassium. Body potassium, has been used as an index of body cell masss, the metabolically active component of the lean tissue. In contrast to body nitrogen, body potassium responds rapidly to feeding by both oral and intravenous routes6,~,g,9,lo. It has been shown that in malnutrition there is a change in muscle membrane potential resulting in reduced intracellular ionic potassium. The reduced cellular potassium cannot be simply corrected by giving potassium but requires restitution of nutrition. The above mentioned observations suggest that cell ion
MITOCHONDRIAL ENERGETICS
BACKGROUND
Oman Failure and Nutrition There are four critical organ systems that are especially likely to fail in aging and critical illness.
They are the cardiovascular, central nervous, musculoskeletal and immune systems.
Relationship of malnutrition to mitochondria) function.
Protein-calorie malnutrition contributes to both skeletal and cardiac' muscle dysfunction in patients with cardiac failure. Muscle is composed of water, minerals, nitrogen and glycogenz,3 Feeding wasted individuals results in a gain of the multiple elements in lean tissue4 including potassium. Body potassium, has been used as an index of body cell masss, the metabolically active component of the lean tissue. In contrast to body nitrogen, body potassium responds rapidly to feeding by both oral and intravenous routes6,~,g,9,lo. It has been shown that in malnutrition there is a change in muscle membrane potential resulting in reduced intracellular ionic potassium. The reduced cellular potassium cannot be simply corrected by giving potassium but requires restitution of nutrition. The above mentioned observations suggest that cell ion
-2-uptake, an energy dependent process, occurs earlier than protein synthesis during nutritional support. This concept has received experimental support by two studies using
3'P-NMR which showed that malnutrition was associated with a reduced rate of oxidative phosphorylation, suggesting a mitochondria) abnormality"°'z Cell energetics are also important for muscle activity and it has been shown'3,'a,~s,~6,»,~s,19,20,21,22 that skeletal muscle function, including that of the diaphragm, can be rapidly altered by nutrient deprivation and restored by refeeding. Also the changes in muscle function are specific to alterations in the nutritional status and are not influenced by sepsis, trauma, renal failure and steroid administration'S~". Christie and Hill indicated that nutritional support improves muscle, including diaphragmatic function before any increase in body protein or body massz°. Windsor and Hillz' demonstrated that the functional effects of nutrition are more important than subnormal body protein as an index of surgical risk. Harming and her colleagues22 demonstrated the ability of stimulated muscle function as demonstrated by a slow relaxation rate and an altered force-frequency curve to predict the ability of patients with cystic fibrosis to grow as an outcome measure. In contrast, body composition, protein biochemistry, muscle power on an ergometer or use of supplements did not predict growth potential. Among the macronutrients, Castenada et ales have shown that protein deficiency can profoundly alter muscle function even when energy intake is sufficient to meet requirements.
The data given above indicate that it is critical to correct protein-calorie malnutrition, with an emphasis on protein repletion, in order to obtain the maximum functional benefits of administering skeletal muscle specific micronutrients. Current diet supplementing strategies for correcting protein-calorie malnutrition focus on giving supplements of protein and energy (carbohydrates and fats). No supplement to date has addressed the cascading series of metabolic abnormalities that can lead to mitochondria) dysfunction.
SUMMARY OF THE INVENTION
We have found that nutrition can be used to prevent or delay the onset of cardiac failure and thereby, promote recovery in disease states affecting the heart. Similar considerations apply to diseases of the other organ systems indicated above.
We have found that the central effect of nutrition in all these systems can be unified into its influence on mitochondria) energetics. That is: inadequate nutitional substrate is a cause of impaired cell energetics. This has led us to invent a composition for the improvement of mitochondria) energetics.
We have shown that in the skeletal muscle protein-calorie malnutrition profoundly reduces mitochondria) oxidative phosphorylation and reduces calcium cycling in cardiac muscle'.
We have found that there is profound reduction of respiratory chain complex I, II and IV activity in animals given a protein-calorie deficient diet. In addition, complex I
activity is similarly reduced in lymphocyte mitochondria showing that these effects are not cardiac specific but apply to mitochondria in other tissues, and protein feeding rapidly restored the abnormality when it was simply due to protein-energy malnutrition (unpublished data).
In addition, certain micronutrients and amino acids also influence mitochondria) function in general. For example, carnitine improves mitochondria) DNA transcription and translation in aged animals24. A specific acyl derivative of carnitine, acetyl-carnitine has been used for mitochondria) DNA synthesis based on findings observed in patients treated with anti-retroviral agents25. Coenzyme Q can alter immune functionz6 and may protect the central nervous system from injury and neurodegenerationz'. On the basis of the above considerations, a nutritional
The data given above indicate that it is critical to correct protein-calorie malnutrition, with an emphasis on protein repletion, in order to obtain the maximum functional benefits of administering skeletal muscle specific micronutrients. Current diet supplementing strategies for correcting protein-calorie malnutrition focus on giving supplements of protein and energy (carbohydrates and fats). No supplement to date has addressed the cascading series of metabolic abnormalities that can lead to mitochondria) dysfunction.
SUMMARY OF THE INVENTION
We have found that nutrition can be used to prevent or delay the onset of cardiac failure and thereby, promote recovery in disease states affecting the heart. Similar considerations apply to diseases of the other organ systems indicated above.
We have found that the central effect of nutrition in all these systems can be unified into its influence on mitochondria) energetics. That is: inadequate nutitional substrate is a cause of impaired cell energetics. This has led us to invent a composition for the improvement of mitochondria) energetics.
We have shown that in the skeletal muscle protein-calorie malnutrition profoundly reduces mitochondria) oxidative phosphorylation and reduces calcium cycling in cardiac muscle'.
We have found that there is profound reduction of respiratory chain complex I, II and IV activity in animals given a protein-calorie deficient diet. In addition, complex I
activity is similarly reduced in lymphocyte mitochondria showing that these effects are not cardiac specific but apply to mitochondria in other tissues, and protein feeding rapidly restored the abnormality when it was simply due to protein-energy malnutrition (unpublished data).
In addition, certain micronutrients and amino acids also influence mitochondria) function in general. For example, carnitine improves mitochondria) DNA transcription and translation in aged animals24. A specific acyl derivative of carnitine, acetyl-carnitine has been used for mitochondria) DNA synthesis based on findings observed in patients treated with anti-retroviral agents25. Coenzyme Q can alter immune functionz6 and may protect the central nervous system from injury and neurodegenerationz'. On the basis of the above considerations, a nutritional
-4-supplement that could maintain or restore mitochondria) function will prevent cardiac failure or aid recovery from cardiac disease. In addition it could also aid in the management of neurodegenerative, musculoskeletal including the muscular abnormality in chronic obstructive lung disease (COPD)~6 and immune disorders.
Heart Failure.
Congestive heart failure has emerged as a major health problem during the past two decades. Its morbidity and mortality have shown a steady increase since 197028; heart failure now affects approximately 1 % of the population of the United States and Canada. These data reflect both the aging of our population and the success of modern cardiovascular medicine in converting acute, often previously fatal, cardiac disease into a more chronic process.
The underlying abnormality in congestive heart disease is myocardial dysfunction leading to inadequate blood flow to peripheral tissues. Although there have been considerable advances in our understanding of the pathogenesis of heart failure in recent years, critical questions remain about the evolution of cardiac dysfunction to terminal failure. The importance of elucidating the mechanisms responsible for the evolution of maladaptive hypertrophy to cardiac failure is emphasized by the fact that in spite of our advances, no presently available therapeutic intervention has been shown to substantially improve the long-term survival of patients with dilated cardiomyopathy and congestive heart failure. The underlying heart disease is relentlessly progressive in almost all patients who develop symptoms of overt failure and mortality continues to be unacceptably high; for example, in a recent heart failure trial, SOLVD, 40% of patients in the symptomatic treated group were dead within 4 years29. Heart transplantation appears to be the only prospect to improve long term survival for many patients.
-$-The reason for this dismal outcome despite modern advances lies in the fact that several metabolic abnormalities have been found in the failing myocardium which together as indicated below result in progressive loss of cardiac myocytes (muscle).
There is a progressive accumulation of calcium in the muscle, which in turn results in increased calcium in the mitochondria. The progressive increase in mitochondria) calcium as well as the basic cardiac disease (ischemic, viral, toxic, genetic) decrease myocyte energy production and increase oxidative stress resulting in free radical damage. The combined result of these three processes promotes myocyte dysfunction and death. In addition these processes also influence skeletal muscle and contribute to fatigue and disability.
The modern pharmacological therapy of heart failure has focused on the amelioration of fluid overload and hemodynamic abnormalities and has not addressed the fundamental fact that if there is progressive loss of cardiac muscle then the patient will inevitably succumb. That is: the inexorable myocyte loss by apoptosis that occurs in heart failure is the key factor responsible for myocardial decompensation and the demise of the patient3°. Oxidative stress, calcium overload and cellular energy deficiency are well known as principal stimuli for the development of apoptosis.
Among the factors that aggravate myocyte dysfunction there is increasing evidence for the role of nutritional deficiencies both due to reduced intake and to insufficient intake in relation to augmented requirements caused by the underlying disease state, a phenomenon which we will refer to as "conditioned deficiency". In this situation the recommended daily allowances (RDA) do not apply, as requirements may exceed the standard RDA.
The presence of protein-energy malnutrition has been recognized by surveys of hospitalized patients using anthropometric, biochemical and immunologic measures of nutritional status.
These surveys have indicated that SO-68% of patients with congestive heart failure were significantly malnourished3~. The proportion of malnourished heart failure patients has been found to be higher than that of patients with cancer, alcoholism or those with acute infection.
The cause of protein-energy malnutrition is due to both reduced intake and increased energy demands. Cardiac failure results in a cascade of metabolic effects such as tissue hypoxia, anorexia, hypermetabolism, weakness, dyspnea and hypomotility of the gastrointestinal tract all leading to poor nutrient intake. Anorexia can be aggravated by unpalatable restrictive diets or by converting enzyme inhibitors or by an excess of diuretics, opiates and digitalis. Characteristics of the disease process such as fatigue and early satiety have all been reported in congestive heart failure patients consuming self selected diets3z~33. These factors lead to compromised food and nutrient intake and subsequently contribute to the poor nutritional status of these cardiac patients.
In addition, patients with heart failure have been shown to have significantly increased resting metabolic rates3a,3s,36,3' possibly due to the increased work of breathing, fever, cytokines or elevated sympathetic nervous system outflow.
The RDA for the vitamins and related micronutrients recommended by federal nutrition authorities in Canada, the United States and Western Europe (e.g. The Canada Food Guide) are obtained through the analysis of deficiency data in otherwise healthy humans and animals.
We have found that with the advent of disease, or due to genetic predisposition, specific metabolic pathways in individual organs and the function of some of these systems alter the nutritional requirements causing conditioned deficiency of both macro-(protein including amino acids, carbohydrates and fats) and micronutrients (electrolytes, trace elements, vitamins and special nutrient substances). Certain pharmaceutical agents or treatment strategies also influence these requirements.
The above considerations indicate that for heart failure and in other conditions detailed below the nutrient intake is instrumental in determining the evolution of tissue damage -its amelioration or acceleration. RDA data, although suitable for a healthy population, are not necessarily appropriate for patients suffering from certain forms of illness or predisposed to sickness through genetic constitution. There is a need for a nutritional supplement that can be taken by persons suffering from illness or with a genetic predisposition to illness.
Musculoskeletal System.
Data given above have clearly demonstrated the relationship of protein deficiency and mitochondria) dysfunction in skeletal muscle. In addition several nutrient agents have been shown to improve skeletal muscle performance. These include creatine, carnitine and taurine.
Central Nervous System.
Mitochondria) dysfunction has been noted as an important factor in several neurodegnerative diseases'e. A central role for defective mitochondria) energy production, and the resulting increased levels of free radicals, in the pathogenesis of various neurodegenerative diseases is gaining increasing acceptance'9.
Immune System.
Immune dysfunction occurs with aging and there is growing evidence that reduced immunity is related to reduced mitochondria) dysfunction4~.
_g_ THE INTERACTING PATHWAYS RESPONSIBLE FOR MITOCHONDRIAL FUNCTION.
We have found that the critical path in these interactions is the flow of energy substrates into the mitochondria through carnitine, the transfer of electrons through the complexes via CoQlO, and the modulation of the calcium pump by taurine. We consider the constituents of this path, namely Carnitine, CoQ 10 and Taurine, to be the core constituents required to promote mitochondria) function. We have found that these compounds act together on this critical path to provide a synergistic effect.
The other constituents of the cascade given in Figure 1 aid the action of this core by modulating oxidative stress which results from external factors and mitochondria) dysfunction and in turn promotes further dysfunction.
Adequate energy production is essential not only for cellular function but also for long term cell survival. Cellular energy production from nutrients, especially fatty acids need the coordinated action of a number of co-factors. Three factors namely, carnitine (critical for the transport of long chain fatty acid substrate), coenzyme Q 10 (a key transducer for mitochondria) oxidative phosphorylation), and taurine (a key modulator of calcium accumulation ) are important in promoting normal cell energetics.
DETAILS OF ALTERED MITOCHONDRIAL ENERGETICS IN HEART FAILURE.
The data for mitochondria) energetic dysfunction has been clearly documented in heart failure and therefore the following details will focus on heart failure as a paradigm.
In heart failure deficiency of carnitine promotes accumulation of toxic long-chain fatty acids;
deficiency of CoQ 10 alters electron transport and mitochondria) calcium accumulation also occurs, which can be corrected by the action of taurine. From Figure 1 it can be seen that normalization of any one of the above three constituents alone will not be sufficient to significantly benefit myocardial energy production in the presence of abnormalities the other factors in the myocardial bioenergetic pathway. In addition, from Figure 1, it can also be seen that the added action of creatine, known to be deficient in cardiac failure and antioxidants to reduce oxidative stress, known to be elevated in cardiac failure, will enhance the action of the three core constituents carnitine, CoQ 10 and taurine. For these constituents to be effective in remodelling the heart, the addition of protein is essential in any supplement.
These substances can be given as oral replacements to benefit both myocyte function and long-term survival.
Details of the deficiencies and altered metabolism of these constituents in cardiac failure and other diseases are given below. However, it has become apparent that this paradigm applies to a number of other diseases; these will be briefly discussed in each section where appropriate.
REGULATING INTRACELLULAR CALCIUM
The failing myocardium exhibits an increase in calcium content and impaired movement of intracellular calcium. Impaired uptake of calcium adversely affects diastolic relaxation whereas the kinetics of transsarcolemmal calcium flux and calcium release by the sarcoplasmic reticulum is a principal determinant of systolic function. Chronic intracellular calcium overload ultimately leads to cell death.
Taurine:
Metabolism and Physiological Role of Myocardial Taurine.
Taurine (2-aminoethanesulfonic acid) is a unique amino acid, which lacks a carboxyl group, and as such it does not enter into protein synthesis. Taurine appears to be an important amino acid for the modulation of cellular calcium levels, exhibiting a remarkable biphasic action by increasing or decreasing calcium levels appropriate to the maintenance of cellular calcium homeostasis4'.az,a3, In the heart, taurine appears to do this by affecting several myocardial membrane systems4'.4z,a3. It is reported to enhance Ca++-induced Ca++ release from the sarcoplasmic reticulum both directly and through inhibition of the enzyme phospholipid methyl transferase, influencing the phospholipid environment of the ryanodine-sensitive calcium channel. It also modulates cardiac Ca++ and Na+ through the cardiac sarcolemmal Na+-Ca++
exchanger and a taurine/sodium exchanger. Taurine also has antioxidant properties and reacts with a variety of potentially toxic intracellular aldehydes including acetaldehyde and malonyldialdehyde44,as Taurine is found in particularly high concentrations in the heart (15 -25mmole/g protein) representing approximately 60% of the free amino acid pool4'.a6. plasma levels are approximately 50 - 80mmo1/L. Taurine is not an essential amino acid in humans as it can be synthesized from cysteine or methionine46; however, most taurine in humans is obtained directly through dietary sources, particularly from fish and milk. Biosynthetic capacity is maturation dependent, being almost non-existent in the human fetus and newborn and progressively increasing until adulthood",48. Taurine uptake by the myocyte is an active process and b-amino acids such as beta-alanine share the transport site; it is saturable at taurine concentrations of 200 mmOle46,a8. In the heart the transport of taurine, like that of carnitine, can be stimulated by beta-adrenergic agonists or dibutyryl-c-AMP; however, in other tissues the c-GMP
pathways seem to be important~b. The taurine transporter of all tissues is regulated by the activation of two calcium sensitive enzymes: protein kinase C (which inhibits the transporter) or calmodulin (which stimulates transport)°8. This reciprocal regulation of intracellular taurine levels by these two enzymes is consistent with a physiologic role for taurine in the maintenance of intracellular calcium homeostasis.
The observation that TNF-a levels49 and soluble TNF receptors5o,s' are raised in heart failure suggest increased cytokine activity in this condition. Grimblesz has shown that the requirement for sulfur containing amino acids is increased when TNF-a is infused. Of greater significance is the fact that transsulfuration of dietary methionine to cysteine is reduced and in consequence levels of taurine and lung glutathione fall unless the animals are supplemented with cysteine.
These findings suggest that with increased cytokine activity as observed by uss' in severe heart failure, the need for cysteine and taurine will increase. Since cysteine will replenish not only taurine but also glutathione (an important endogenous antioxidant -see 'Oxidative Stress' section, below), it may be an important supplement for replenishing both.
Taurine Levels and Taurine Supplementation in Heart Failure.
Cardiac taurine concentrations are altered in heart disease. Cats have very little taurine biosynthetic capacity and may exhibit a taurine deficient cardiomyopathys3.
Prolonged taurine depletion of the myocardium has been shown to decrease contractile force through reduction of myofibrilss'. This finding is of interest because increased calcium levels in the myocyte can activate calcium dependant proteinases that in turn can lead to the breakdown and loss of myofibils54. Taurine depletion also renders the heart more susceptible to ischemic injury55. In this context it should be noted that myocardial taurine depletion has been reported following acute ischemic injurysb and cardiovascular bypass surgerys' In species other than the cat, myocardial hypertrophy and failure is associated with an increase in cardiac taurine concentration4'~58. In spite of this increase, orally administered taurine has been shown to have a cAMP-independent positive inotropic effect in animal models of left ventricular dysfunction'. Taurine administration has been shown significantly reduce calcium overload and myocardial damage in a variety of heart failure models including that induced by the calcium paradox, doxorubicin or isoproterenol or in hamster cardiomyopathy4'°s9,bo,6',62; it also has been reported to increase the survival of rabbits with aortic regurgitation63.
Taurine may have a beneficial effect on cardiac arrhythmiasb' including those associated with digitalis or catecholamine excessbs. Studies of taurine administration in humans have been limited. However, in patients suffering from congestive heart failure taurine, given in an oral dose of 1 gram three times per day, has been reported to be extremely well tolerated and to improve both hemodynamic state and functional capacity4',66.67 Taurine also appears to function as an osmoregulator and neuromodulator in the brain6g. In addition there is evidence that taurine modulates calcium influx and efflux in the brain, increases resistance to hypoxia and reduces seizure activity when administered intraperitoneally. In streptozotocin-induced diabetic rats taurine also appears to protect against the development of renal dysfunction45; cardiac studies have not been performed in this model. On the same lines taurine also protects the kidney and liver against doxorubicin (adriamycin) toxicityb9.
MYOCARDIAL ENERGETICS
L-Carnitine:
Carnitine in Health and Disease:
L-carnitine, an amino acid derivative (3-hydroxy-4-N-trimethylaminobutyric acid), plays a critical role in this bioenergetic pathway as it is essential for the transport of long-chain fatty acids from the cytoplasm into the sites of beta-oxidation within the mitochondria) matrix.'° The importance of carnitine has been recognized by the observation that carnitine deficiency occurs in several genetically determined metabolic abnormalities">'z where it is associated with the development of cardiomyopathy and skeletal muscle dysfunction. L-carnitine administration to these patients restored to a great extent cardiac and skeletal muscle function.
Evaluation of carnitine metabolism in several cardiac pathologies has led to the realization that carnitine deficiency may also be acquired and organ selective, a finding of great significance because fatty acid oxidation is a major source of energy for the myocardium.
The impaired heart, regardless of the etiology of the dysfunction (including ischemic or non-ischemic dilated cardiomyopathy, coronary, hypertensive, diabetic and valvular heart disease), exhibits a marked depletion (up to 50%) of myocardial carnitine levels (particularly free carnitine) in both animal models and man'3>'4,'s, with evolution of the heart disease. On the other hand, despite low cardiac levels, plasma carnitine levels increase'6. This finding makes plasma levels unrepresentative of the levels in the heart.
In addition to promoting the entry of fat into the mitochondria, carnitine binds acyl groups and releases free CoA. These processes benefit the myocyte in two ways, first it removes toxic short chain acyl groups and second maintains sufficient amounts of free CoA for mitochondria) function.
An example of the detoxifying action of carnitine is seen in the ischemic myocardium"~'g. In ischemic myocardium or skeletal muscle there is an accumulation of long chain acyl-CoA; these compounds are potentially toxic as they exhibit both detergent-like properties and can impair mitochondria) energy production through the inhibition of a mitochondria) membrane enzyme, adenine nucleotide translocase, which transfers newly synthesized ATP from the inner mitochondria space into the cytoplasm. Carnitine protects the heart (or skeletal muscle) from the accumulation of these metabolic poisons by forming acylcarnitines, which can freely diffuse out of the cell and be eliminated through the urine.
Carnitine deficiency has also been observed in patients with chronic renal failure; an improvement in cardiac function following carnitine therapy has been reported for those on hemodialysis'9.
Carnitine Supplementation and Treatment:
Body stores of 1-carnitine are supplied by both diet and via endogenous biosynthesis from trimethyllysine. The concentration of carnitine in normal adult cardiac and skeletal muscle is approximately 8 - I S nmol/mg non-collagen protein; plasma levels are approximately 35 - 50 mmol/L. Thus plasma levels are generally not good measures of tissue concentrations. Under normal conditions approximately 80% of carnitine is free and the remainder complexed as fatty acylcarnitine. A 20-SO:I intracellular to extracellular carnitine gradient is maintained by a sodium-dependent plasma membrane transport system. Carnitine transport can be stimulated by beta-adrenergic agonists or dibutyryl-cAMP.
Following oral administration, peak plasma concentration occurs at 3 hours and decays with a T"Z of 3 - 4 hours; the turnover of endogenous cardiac or skeletal muscle carnitine is likely on the order of several days. The bioavailability of I-carnitine is limited to approximately 5 - 20%
probably due to clearance by the liver. L- carnitine is well tolerated and no adverse effects have been described.
Acetyl-1-carnitine and proprionyl-1-carnitine are naturally occurnng derivatives of 1-carnitineg°.
Acetyl-1-carnitine has been shown to influence mitochondria) DNA synthesis, is depleted by antiretroviral drugs and is non-toxic when infused intravenouslyg'. The administration of acetyl-I- carnitine has been shown to effectively replace decreased carnitine stores in the brain and heart associated with aging in rats82. Acetyl-1-carnitine has excellent penetration of the CSF and is likely to be of benefit in neurodegenerative conditions such as Alzheimer's diseaseg'~g3. Acetyl-I-carnitine has also been shown to be of benefit to peripheral nerve function in experimental diabetes8°.
Proprionyl-1-carnitine has also been used for cardiac therapy85~86~8'~88.
Proprionyl-1-carnitine directly penetrates the cell membrane and has a high affinity for the protein carriers; within the mitochondria the enzyme carnitine acetyl transferase releases 1-carnitine and proprionyl-CoA and the latter is transformed into succinyl CoA which can prime the citric acid cycle and the production of ATP89~9o. The proprionyl group appears to stimulate fatty acid oxidation (whereas the acetyl group inhibits this)$'.
L-carnitine (3 - 5 grams) or proprionyl-1-carnitine (1.5 - 3.0 grams) administration has been shown to result in significant hemodynamic improvement and an overall benefit in the functional capacity of animals and patients with heart failure or myocardial lSChemla'2''3,79,85,86"91,92.93,94,95,96,97,98,, Clinical studies report a reduction in cardiac damage, when I-carnitine is taken from 4 - 12 weeks following myocardial infarction'g~92. It also appears to benefit patients who suffer from skeletal muscle ischemia manifested as intermittent claudication. Circulating levels of tumour necrosis factor, a cytokine that leads to muscle wasting and cardiac dysfunction, correlates with functional class and prognosis of patients with heart failures'; in this context it is of interest that proprionyl-1-carnitine administration tends to normalize the circulating levels of this cytokine in patients with heart failure98.
Ubiquinone or Coenzyme Q10:
CoenTjymeQlO in Health and Disease'°"'°""°a.°
99).
Coenzyme Q 10 or ubiquinone (2,3 dimethoxy-5 methyl-6-decaprenyl benzoquinone) plays a vital role as a rate-limiting carrier for the flow of electrons through complexes I, II and III of the mitochondria) respiratory chain. It is also a major endogenous lipophilic antioxidant and, like vitamin C, can regenerate a-tocopherol, the active form of vitamin E by reducing the a-tocopherol radical. A deficiency of ubiquinone caused by actual loss or through oxidation of the molecule can result in an impairment of energy production. The molecule is sited within the inner mitochondria) membrane but is also associated with the membranes of other intracellular organelles. It is also an important component of circulating LDL particles, protecting LDL from oxidation.
Ubiquinone is actively biosynthesized with the cells. The quinone ring is synthesized from the amino acid tyrosine and the polyisoprenoid side chain is formed through the acetyl CoA -mevalonate pathway. The latter pathway is under the control of the enzyme hydroxy-methylglutaryl coenzyme A reductase (HMGCoA reductase) and is also used for cholesterol synthesis; inhibition of this pathway using HMGCoA reductase inhibitors, drugs which decrease -1~-plasma cholesterol, also results in a parallel decrease in plasma ubiquinone'°° and may also reduce tissue ubiquinone levels'°' Significantly reduced levels of myocardial ubiquinone are found in heart failure in both animal models and man'°2,'o3.~oa, Since the heart depends upon aerobic oxidation for its energy needs, ubiquinone, which is critically necessary for oxidative energy production is very important for cardiac function. The antioxidant properties of ubiquinone would add to this benefit.
Ubiguinone Sunnlementation and Treatment ,99,105,106,107 Ubiquinone is widespread throughout all food groups and thus body stores may also be partially supplied by diet. The concentration of ubiquinone in normal cardiac muscle is approximately 0.4 - 0.5 mg/mg dry weight, slightly less in skeletal muscle and 0.6 - l.3mg/ml in plasma. Oral absorption is slow and markedly enhanced in the presence of lipid; plasma levels peak at 5 -10 hours and decay with a T"~ of 34 hours. There is a large hepatic first pass effect so that only about 2 - 5 % of an oral dose is taken up by the myocardium. The mean steady state level in plasma increases 4 - 7 fold after 4 days of dosing at 100 mg 3 times daily.
Side effects are virtually absent; however, asymptomatic elevations in liver enzymes (LDH, SGOT) have been described with doses of 300 mg/day.
Oral ubiquinone therapy has been shown to result to beneficially affect cardiac dysfunction in a variety of animal paradigms'°g~'o9,"0. Oral ubiquinone also has been reported to reduce the age-associated decline in mitochondria) respiratory function in rat skeletal muscle"'. The controlled trials in patients with heart failure show clinical benefit, reducing symptoms, lessening hospitalization and improving myocardial performance99°'o2.~o3,~os,.az>a3.aaa~s.
Creatine:
Role of Creative in Health and Disease.
Creative phosphate (PCr) is the primary high-energy phosphate reservoir of the heart and skeletal muscle. High-energy phosphate is transferred from PCr to ADP to form ATP
through catalysis by creative kinase"6:
PCr + ADp + H+ <__> ATP + Cr Muscle creative stores are maintained through biosynthesis from endogenous precursors arginine, glycine, and methionine in the liver, pancreas and kidneys, and through the ingestion of meat and fish. The concentration of total creative in normal adult human myocardium or skeletal muscle is approximately 140 mmol/g protein; creative phosphate constitutes about 65 - 80% of the total creative under aerobic conditions"6. Creative is accumulated by muscle against a large concentration gradient from the blood; the transporter is probably driven by the extracellular/intracellular Na+ electrochemical potential"6°"'. Tr~ere is evidence that increased adrenergic drive (a characteristic of heart failure) can decrease myocardial creative and creative kinase stores'zs, ~za, Experimental creative depletion in animals results in structural, metabolic and functional abnormalities in muscle"'. Myocardial creative content and myocardial energetics is reduced in a wide variety of animal paradigms of heart fallure'16,118,119.123,120. No data is available regarding creative replacement in these models. However creative has been shown to attenuate myocardial metabolic stress in rats caused by inhibition of nitric oxide synthesis'z' Hearts from patients with coronary artery disease, aortic stenosis or heart failure all show a marked reduction in total creative (up to SO%) with an expected concomitant reduction in creatine phosphate'zzaz3; creatine kinase is also reduced"6~"'. These reductions interact synergistically decreasing myocardial capacity for ATP synthesis by up to 80%"6~' ~'~'za. Such an energy deficit has a significantly adverse impact on myocardial function and survival. Similar abnormalities of energy stores and production are seen in the skeletal muscles of patients of heart failure; these play an important role in compromising the functional capacity of these patients'zs.
Recently, it has been reported that the myocardial PCr/ ATP ratio may be a better predictor of patient mortality in dilated cardiomyopathy than left ventricular ejection fraction or the patient's functional class'zb.
Creatine Supplementation and Treatment.
The role of creatine supplementation may not be observed in normal cardiac or skeletal muscle under normal levels of performance. However, supplementation has been shown to increase performance in situations where the availability of creatine phosphate is important'z'aza, Ingestion of 3 g of creatine per day for one month (or 20 g per day for one week) increases muscle creatine content and can improve performance'z9. Daily turnover of creatine to creatinine for a 70 kg male has been estimated to be approximately 2 g99. Creatine supplements will increase skeletal muscle creatine and increase muscle resistance to fatigue during short-term intense exercise where it reduces lactate accumulation'3o,'3','3z. It also appears to be of benefit when given in adequate doses to patients with heart failure where myocardial and perhaps skeletal muscle creatine and creatine phosphate levels are depressed. The administration of a creatine supplement to patients with heart failure did not increase cardiac ejection fraction but significantly increased not only skeletal muscle creatine phosphate but also muscle strength and endurance'33 and thus would benefit patient symptom-limited performance.
Thiamine:
Thiamine or vitamin B, status may be compromised in heart failure due to a variety of causes.
Thiamine is a water-soluble vitamin which functions as a coenzyme in a variety of enzyme systems especially those related to energy metabolism. Thiamine is stored in very small quantities (approximately 30 mg) with approximately half of the body stores being found in skeletal muscle with the remainder being found in the heart, kidney and nervous tissue including the brain. Since little is stored, thiamine requirements must be met daily.
Thiamine requirements are related to daily energy expenditure'3a and metabolizable energy intake, especially carbohydrate intake and therefore patients with increased metabolic rates or poor intakes, such as those with heart failure, may be at increased risk for deficiency during acute illness'3a,'3s. T'he Food and Nutrition Board, USA recommends that for adults with energy intakes below 2000 kcal/day that a basal requirement of 1.0 mg thiamine per day be maintained'36. The Canadian recommendations support an intake of 0.4 mg/1000 kcal or no less than 0.8 mg/day for adults'3'. Thiamine intake in patients with heart disease has been examined in only one study using a semi-quantitative food frequency questionnaire focusing on foods high in thiamine'38. Nutrient analysis indicated a low overall intake of thiamine of 0.966 mg/day with 33% of patients not meeting the Recommended Dietary Allowance (RDA) for thiaminebs. This study also indicated that thiamine-deficient diets were more common among patients treated as out-patients rather than in-patients.
Necropsy studies indicate that thiamine deficiency is underdiagnosed in life'35. Classical deficiency signs are often absent or they are not recognized'39. Thiamine deficiency results in beri beri, which can have neurological or cardiac effects. The symptoms that are most common are mental confusion, anorexia, muscle weakness ataxia, edema, muscle wasting, tachycardia and an enlarged heart'4°. Thiamine deficiency leads to several major derangements of the cardiovascular system including peripheral dilatation leading to a high output state, biventricular myocardial failure, retention of sodium and water leading to edema as well as a relative depression of left ventricular function with low ejection fraction'4°'"'. This picture will be masked in preexisting low-output heart failure. Since thiamine deficiency will exacerbate co-existing heart failure, correction of this deficiency through supplementation has the potential to improve cardiac status in patients with congestive heart failure.
In addition to poor dietary intake and increased metabolic utilization, referred to above, patients with heart failure also may be at risk for thiamine deficiency because of their need for diuretics.
There is evidence from both animal and human studies that diuretics, especially those which affect the Loop of Henle such as furosemide, cause increased urinary losses of thiamine even in the presence of thiamine deficiency'42,'a3. It appears that furosemide treatment may block the kidneys' ability to adapt thiamine excretion in order to prevent thiamine deficiency. These data demonstrate that patients with heart failure are at increased risk of thiamine deficiency due to a combination of 1 ) poor intake resulting from anorexia and unpalatable diets, 2) hypermetabolism, and 3) enhanced excretion caused by the concurrent use of diuretics.
There have been a handful of studies which support a high prevalence of thiamine deficiency in both in- and outpatients with congestive heart failure - from 13% to 91%
depending on the population studied'3g~'a3,~aa,~as, A very high (91%) prevalence of thiamine deficiency has been reported in a group of congestive heart patients on long-term furosemide treatment'a3. The average dose of furosemide ranged from 80-240 mg/day. Biochemically, the furosemide-treated group had severe thiamine deficiency indicating that doses of this magnitude have significant effects on thiamine status. These investigators undertook a randomized double-blind trial of thiamine supplementation in 30 in-patients with heart failure and on long-term furosemide therapy'46. Patients were randomized to receive 200 mg intravenous thiamine or a placebo for seven days after which all subjects were placed on an oral supplement of 200 mg/day of thiamine and followed for an additional six weeks. They saw a significant diuresis with increased excretion of sodium and water within two days of thiamine supplementation in comparison with the placebo group whose excretion remained constant. The mean left ventricular ejection fraction increased significantly after one week of thiamine supplementation but not with the placebo. After six weeks of oral thiamine supplementation left ventricular ejection fraction was increased by 22%. This study demonstrates a significant improvement in left ventricular function as a result of thiamine supplementation in patients with CHF. In addition, improvement in left ventricular function was accompanied by diuresis and increased sodium excretion, which is hypothesized to be one of the major effects of thiamine supplementation.
Finally, it should also be noted that thiamine deficiency is also commonly present in patients on hemodialysis'4', in patients in intensive care units'48 and perhaps cognitive impairment in the aged' 49.
REDUCING OXIDATIVE STRESS
Cells are constantly subjected to interplay between free radical injury and protective mechanisms to prevent or minimize free radical injury. Oxidative stress has been defined as a disturbance in the equilibrium between pro- and anti-oxidative systems. A number of different challenges increase oxidative stress resulting in damage to lipids, proteins, DNA and carbohydrates.
Dietary Antioxidants - Vitamin E, Vitamin C, Cysteine and Selenium -counteract the effect of free radicals generated by external factors and by mitochondria) dysfunction.
Cysteine is the precursor of glutathione, one of the most potent antioxidants present in the cell.
Role of Oxidative Stress in Cardiac Disease.
Until recently there has been a reluctance to accept that oxidative stress can be important in the pathogenesis of cardiac disease however, recent investigation suggests that oxidative stress may be a very important contributor to the deterioration of the hypertrophied or failing myocardium.
For example, reactive oxygen species have been shown to be critical components of the apoptosis pathway's°; myocyte loss by apoptosis is now thought to be a significant contributor to the inexorable deterioration of the failing myocardium's'. The importance of oxidative stress in heart failure is not surprising because a number of factors associated with heart failure, such as increased plasma catecholamines,'sz and cardiac sympathetic tone's3, microvascular reperfusion injury'sa>>ss cytokine stimulation49~so and mitochondria) DNA mutations (particularly complex I)'sb are known stimuli for free radical production and oxidative stress's'~'ss,~s9,~6o. Coenzyme Q10 and taurine (and its precursor cysteine), discussed above are important endogenous antioxidants or antioxidant precursors.
Peroxidative damage has been demonstrated in the hearts of dogs, guinea pigs and rats with heart failure due to pressure or volume overload'6'.'62,'63. Vitamin E
administration benefited'' both myocardial structure and function. We have observed decreases in the levels of glutathione peroxidase and a-tocopherol and a concomitant increase in protein oxidation in the myocardium of cardiomyopathic hamsters during the late stages of hamster cardiomyopathy'bs ; an elevation of myocardial free radicals and lipid peroxides have also been demonstrated in this model'66. The administration of vitamin E appears to completely normalize these findings'63.
Recently, we have also demonstrated a significant increase in the plasma level of lipid peroxides and malonyldialdehyde, markers of oxidative stress, in patients suffering from congestive heart failures'. The increase in oxidative stress was related to the clinical severity of heart failure with the highest levels of lipid peroxidation and malonyldialdehyde being observed in class 3 and class 4 patients. Increased free radical activity is also seen in patients on life support or in intensive care unit settings'6'. These observations suggest that antioxidant supplements should be important additions to the therapy of heart failure and severely ill patients.
The ability to withstand peroxidative injury is partially dependent on diet. A
good dietary intake of the antioxidant vitamins C and E, and trace nutrient minerals such as selenium together with adequate cysteine as a precursor for glutathione synthesis are important for protection against free radical injury. Fat intake and composition is also important, the need for vitamin E may be increased by an increased intake of polyunsaturated fatty acids'6s. It has been suggested that the vitamin E requirement = 5.96 + 0.25 (% PUFA kcal + g PUFAs). With the North American diet increasing in PUFA, Diplock has suggested that the current RDA (recommended daily allowances) be increased fourfold'69. Dietary antioxidants may reduce the risk of ischemic heart disease and the extent of myocardial infarction"°'"'°"z. Recent reports suggest an increased need for vitamin C in patients with diabetes mellitus"3. Finally oxidative stress is also felt to be a major contributor to chronic neurodegenerative disease and the tissue deterioration and immune dysfunction associated with aging"'' "s, »6, "', as, X79, ~so, ~s~, ~sz, ~s3,~sa.
Correction of Mitochondria) Abnormalities.
Other investigators have used certain of these nutrients alone. We have found that a preferred nutritional supplement would replace the constituents given above and influence several metabolic pathways interacting to subserve mitochondria) function. We have found that replacing only one of the core constituents will not correct the connected abnormalities in multiple parts of the myocardial bioenergetic pathway which is deranged in cardiac failure.
Rather, our supplement helps to correct the cascading series of metabolic abnormalities in patients with myocardial dysfunction and other diseases mentioned above, rather than merely a problem at a single point in a pathway.
In a preferred embodiment, the invention relates to a method of medical treatment of a disease, disorder or abnormal physical state in a mammal selected from the group consisting of heart disease and functional deterioration associated with ageing, the method comprising administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or its precursors in a single or divided daily dose.
In one variation, the method includes administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine, Coenzyme Q10 (Ubiquinone) and Taurine or its precursors in a single or divided daily dose. The mammal is preferably one of the group including humans, dogs, cats and horses. The disease, disorder or abnormal physical state may include a disease, disorder or abnormal physical state that is due in whole or in part to aging.
Another variation of the invention includes a method of increasing neuromuscular or muscular or athletic performance in a mammal, the method including administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or its precursors in a single or divided daily dose. Another aspect of the method includes administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Camitine, Coenzyme Q10 (Ubiquinone) and Taurine or its precursors in a single or divided daily dose. The mammal is preferably one of the group including humans, dogs, cats and horses. The method and composition improves functional performance and muscular performance. In one embodiment, for an 80 kg man, suitable amounts would include at least about 2.7g taurine, at least about 2.7g L-carnitine and at least about 135 mg of CoQlO.
BRIEF DESCRIPTION OF THE DRAWINGS.
Figure 1 is a schematic diagram of the interaction of the nutrients included in this invention and their interaction in cell energetics.
Figure 2 shows electron micrographs of heart specimens from hamsters in Experiment 1. (a) control non-treated heart (b) cocktail treated heart (c) normal hamster heart.
Figure 3 shows the mean pressure of contraction of hamster hearts (Langendorff Model) in Experiment 1. (a) normal hamster heart (b) control non-treated heart (c) control non treated heart (d) control non-treated heart and cocktail treated heart (e) cocktail treated heart (f) cocktail treated heart.
Figure 4 shows plasma vitamin E levels as a measure of compliance.
Figure 5 shows that exercise capacity at 12 weeks with the supplement increased by approximately 30%.
Figure 6 (a) shows a preferred embodiment of a supplement of the invention.
One packet includes about 125 mL of solution. About 250 mL is the recommended daily dose for a human (preferably for a male of about 80kg). Variations of this embodiment may be made. For example, many of the compounds indicated in brackets on the chart may be varied, such as to use forms of Vitamin C other than the specific form indicated in brackets. Masses used in variations are preferably at least about those masses listed in the chart. As well, specific changes include using at least about 67.Smg of Coenzyme Q10, at least about 1.35g of L-carnitine , at least about 875 mg of creatine and at least about 1.35 g of taurine per pack. Each pack includes about 125mL of solution (carrier). These amounts are preferably given at 250mL daily in a single or divided daily dose. (b) shows a variation of the supplement. Amounts greater or less than than the masses (including ranges, where shown) shown in figures 6(a) and (b) may be administered depending on individual need. In another variation of the supplement of the invention, carnitine, taurine, and coenzyme Q 10 may be administered alone.
DETAILED DESCRIPTION OF THE INVENTION
Researchers have not recognized that optimizing mitochondrial function depends upon the synergistic correction of cellular and mitochondrial energy substrates (Figure 1 ) which will lead to improved energetics, reduced oxidative stress and better calcium homeostasis, a synergistic response clinically beneficial to the patient.
The conventional approach has been to try single nutrients. This has led to conflicting results, at best.
The combination of nutrients of this invention addresses what we have found to be an interrelated series of disruptions in cellular metabolism, that are present in heart failure and conditions such as aging, chronic neurodegenerative disease, immune diseases such as AIDS, chronic multisystem disease, chronic lung or renal disease, chronic fatigue syndrome, patients on immunosuppressive drugs post-transplantation, cancer patients on doxorubicin or related drugs, wasting or cachexia from cancer or sepsis and in normal humans wishing better neuromuscular or athletic performance, and thus provides more reliable, effective treatment.
The combination is preferably delivered orally, but other methods of administration such as intravenous administration may be used.
The invention is a nutritional supplement that helps to correct or prevent the cascading series of metabolic abnormalities responsible principally for cardiac disease but will have a similar effect on neuromuscular, central nervous and immune system dysfunction in a wide variety of diseases.
Rather than merely addressing problems at particular points in metabolic pathways, the nutritional supplement of the invention uses a holistic approach to restoring and improving function at many points in cell metabolism, for example at multiple points along the mitochondria) bioenergetic pathway. The effectiveness of this nutritional supplement in preventing and correcting myocardial dysfunction has been demonstrated in vivo (Example 1 ).
This invention relates to a dietary supplement comprising effective amounts of L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-1-Carnitine), Coenzyme Q 10 (Ubiquinone or its functional analogues) and Taurine as the minimal number of core constituents essential for the correction of the abnormality in mitochondria) energetics in cardiac failure and the different diseases referred to above. Additional supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopheryl), Vitamin C (ascorbic acid), Selenium, and Thiamin in a high protein nutritional feeding are preferred.
This invention relates to a dietary supplement taken in a high protein formulation such as a dairy based drink, a dehydrated dairy product, Soya based drink or dehydrated product, or a nutritional bar which may contain: L-Carnitine 0.5-5 g or its functional analogues such as Acetyl- and Proprionyl-1-Carnitine 3 g, Coenzyme Q10 (Ubiquinone) 30-200 mg (preferably at least about 150 mg) or its functional analogues, Taurine 0.1-3 g. Addition of Cysteine O.Sgm-1.5 g, Creatine 2.5 g, Vitamin E (RRR-d-alpha-tocopheryl) 600 IU, Vitamin C (ascorbic acid) 1000 mg, Selenium 50 mcg, Thiamine 25 mg will aid the action of the core constituents.
These doses may vary 25% to 300% for specialized formulations. Coenzyme Q10 (Ubiquinone) preferably is at least about 1 SO mg.
This formulation ensures a high quality protein to optimize muscle function so as to allow the above nutrients in combination to synergistically interact for the benefit of the patient - that is the effect of all of the ingredients combined will be greater than the sum of the individual parts as they address a cascading series of metabolic abnormalities. There is a core of specific nutrients, which must be combined to be effective, and a larger number for optimal effectiveness.
Conversely omission of the core will detract from the overall efficacy of this supplement. In addition to maintaining protein stores, the supplement corrects abnormalities in: (a) myocardial energetics, (b) intracellular calcium and (c) oxidative stress.
This supplement also benefits patients, with or without heart failure, with other conditions in which cellular nutrition, mitochondrial energetics and function are impaired or less than desired and oxidative stress is increased, including but not exclusively for musculoskeletal, immune and disorders of the central nervous system especially those related to aging.
Such disorders include neurodegenerative disease, immune diseases, stroke, AIDS, chronic multisystem disease, respiratory muscle fatigue such as chronic obstructive lung disease, lung or renal disease, chronic fatigue syndrome, patients on immunosuppressive drugs, cancer patients treated with drugs such as doxorubicin, wasting, cachexia from cancer or sepsis Effectiveness of Nutrient Cocktail In Vivo:
In vivo data gained from cardiomyopathic hamsters showed the synergistic effect of the nutritional supplement (Experiment 1 ). It also showed the feasibility of providing a cocktail of nutrients to cardiomyopathic hamsters and that the mixture positively affected cardiac structure, function and markers of oxidative stress, deterioration of mitochondrial and myofibrillar structures in non-treated animals with improved preservation in treated animals. The results show that there are increased areas of necrosis in non-treated hearts in comparison with treated hearts. These results show that this cocktail of nutrients is effective in preserving myocyte function and structure.
Example 1 - Cardiac Nutrient Cocktail Study We performed a pilot study in order to determine the feasibility of providing a "cocktail" of nutrients as well as their effect on indices of oxidative stress as well as on myocardial structure and function.
Composition of Cardiac Cocktail L-carnitine 300 mg/kg/day V itamin E 147 mg/kg/day Vitamin C 100 mg/kg/day Coenzyme Q,o 15 mg/kg/day Thiamine (B,) 100 mg/kg Cysteine 12 mg/day Selenium 0.05 mg/day (S mglkg diet) Taurine 188 mg/day ( 18.8 g/L) Creatine 100 mg/day ( 1 % diet) Method of Delivery The nutrients were delivered in l Oml of raspberry Jell-O. Water soluble nutrients were added directly to the cooled Jell-O while lipid soluble components were mixed with 15 ml 20%
intralipid prior to their addition to the cocktail mixture.
Study Design 180-day old cardiomyopathic hamsters were started on supplementation after a two-week acclimation period. 18 animals received Jell-O supplemented with nutrients while 18 received the identical Jell-O but without nutrients. The animals received full supplementation for eight weeks, at this time the animals were 278 days of age. At this time, 6 treated, 6 untreated and 6 non-diseased hamsters underwent the Langendorff procedure modified for hamsters following which the hearts were preserved for electron microscopy. The remaining animals were sacrificed and blood, hearts, livers and muscle were collected for biochemistry.
Results a) Mortality - In the treated group, 2 hamsters died. Of the non-treated group, 4 hamsters died with an additional hamster being moribund at the time of study.
b) Appearance - The treated hamsters remained active and alert with no visible edema. In contrast, two of the non-treated animals became grossly edematous with exceptionally large black livers. The control non-treated animals were less active and appeared less bright.
c) Biochemistry - The heart and plasma were analysed for indices of oxidative stress.
Control - Non Cocktail Treated Treated Heart Glutathione Peroxidase 113.05 ~ 8.20 134.34 t 16.7 Activity Units/min/mg protein Heart Malondialydehyde ug/g 2.00 ~ 0.25 1.67 ~ 0.22 wet weight Plasma Malondialydehyde nmol/ml0.17 ~ 0.009 0.14 ~ 0.04 plasma Plasma Glutathione Peroxidase 5.24 ~ 0.82 6.03 t 0.51 Activity Units/min/mg protein Ratio Heart Weight: Body Weight0.008 t 0.0007 0.007 ~ 0.0006 D. Function Non-Treated Treated Normal Hamster * Mean Pressure - 20.84 + 5.97 44.17 t 4.55 92.50 ~ 11.99 Langendorff mmHg * See attached tracings (Figures 3(a)-(f)) d) Microscopy - Electron micrographs (Figures 2 (a)-c)) show deterioration of mitochondria) and myofibrillar structures in non-treated animals with markedly improved preservation in treated animals. In addition, there are increased areas of necrosis in non-treated hearts in comparison with treated hearts. The results achieved were superior to those projected from individual studies of the ingredients.
e) Recently we have completed another study with the supplement and confirmed all the above results and in addition have shown a complete restoration of systolic contractility as measured by +dP/dT and diastolic relaxation as measured by -dP/dT.
Conclusions Nutrients have been used, singly or in random combination to treat several conditions including heart disease. We by contrast have found that three defined key components, L-carnitine, coenzyme Q 10 and taurine, interact in a way which potentiates the action of each on cell function and energetics. Creatine, thiamine and antioxidants support the action of this core. In addition protein enrichment also aids the maintenance of mitochondria) energetics. We have demonstrated the validity of this claim by preventing the development of heart failure in a genetic animal model normally subject to the inexorable progression of heart failure culminating in death. Other studies using nutrients have not shown comparable benefit.
In another embodiment of the invention, the nutritional supplement is adapted in an amount effective for administration to humans for the purpose of enhancing muscular or athletic performance.
A randomized placebo-controlled safety and efficacy study of a liquid supplement, containing about: 2.7 grams of taurine, 2.7 grams of carnitine, 135 mg coenzyme Q10 plus antioxidant vitamins (vitamin E - 400IU, Vitamin C - 250 mg) and 1.75 grams of creatine per 250 milliliters was performed in 33 healthy untrained human volunteers. The supplement was given for 12 weeks at 125m1 twice daily.
There were 2 dropouts in the placebo group between weeks 4 and 12. There were no dropouts in the active supplement group. Exercise capacity, measured as time until exhaustion at 110% of individual V02 max, was assessed at baseline and at weeks 4 and 12. Figure 4 shows plasma vitamin E levels as a measure of compliance. Figure 5 shows the results where exercise capacity at 12 weeks with the supplement increased remarkably by about 30%.
The nutritional supplement of may be adapted (appropriate to body mass and metabolic rate) to be administered to humans and other mammals, such as dogs, cats and horses, in amounts effective for correcting diseases, conditions and infirmities described in this application, including those due to aging. They may also be adapted (appropriate to body mass and metabolic rate) to be administered to humans and other mammals to enhance muscular performance.
Mammals tend to have a high and variable metabolic rate. Their requirements per gram of tissue differs from humans. By way of example, a rat has about four times the metabolic rate of a human. The amounts to be administered will also vary with the age of the mammal. The appropriate amount to be administered will be apparent to one skilled in the art.
The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. All such modifications are intended to be included within the scope of the appended claims.
Heart Failure.
Congestive heart failure has emerged as a major health problem during the past two decades. Its morbidity and mortality have shown a steady increase since 197028; heart failure now affects approximately 1 % of the population of the United States and Canada. These data reflect both the aging of our population and the success of modern cardiovascular medicine in converting acute, often previously fatal, cardiac disease into a more chronic process.
The underlying abnormality in congestive heart disease is myocardial dysfunction leading to inadequate blood flow to peripheral tissues. Although there have been considerable advances in our understanding of the pathogenesis of heart failure in recent years, critical questions remain about the evolution of cardiac dysfunction to terminal failure. The importance of elucidating the mechanisms responsible for the evolution of maladaptive hypertrophy to cardiac failure is emphasized by the fact that in spite of our advances, no presently available therapeutic intervention has been shown to substantially improve the long-term survival of patients with dilated cardiomyopathy and congestive heart failure. The underlying heart disease is relentlessly progressive in almost all patients who develop symptoms of overt failure and mortality continues to be unacceptably high; for example, in a recent heart failure trial, SOLVD, 40% of patients in the symptomatic treated group were dead within 4 years29. Heart transplantation appears to be the only prospect to improve long term survival for many patients.
-$-The reason for this dismal outcome despite modern advances lies in the fact that several metabolic abnormalities have been found in the failing myocardium which together as indicated below result in progressive loss of cardiac myocytes (muscle).
There is a progressive accumulation of calcium in the muscle, which in turn results in increased calcium in the mitochondria. The progressive increase in mitochondria) calcium as well as the basic cardiac disease (ischemic, viral, toxic, genetic) decrease myocyte energy production and increase oxidative stress resulting in free radical damage. The combined result of these three processes promotes myocyte dysfunction and death. In addition these processes also influence skeletal muscle and contribute to fatigue and disability.
The modern pharmacological therapy of heart failure has focused on the amelioration of fluid overload and hemodynamic abnormalities and has not addressed the fundamental fact that if there is progressive loss of cardiac muscle then the patient will inevitably succumb. That is: the inexorable myocyte loss by apoptosis that occurs in heart failure is the key factor responsible for myocardial decompensation and the demise of the patient3°. Oxidative stress, calcium overload and cellular energy deficiency are well known as principal stimuli for the development of apoptosis.
Among the factors that aggravate myocyte dysfunction there is increasing evidence for the role of nutritional deficiencies both due to reduced intake and to insufficient intake in relation to augmented requirements caused by the underlying disease state, a phenomenon which we will refer to as "conditioned deficiency". In this situation the recommended daily allowances (RDA) do not apply, as requirements may exceed the standard RDA.
The presence of protein-energy malnutrition has been recognized by surveys of hospitalized patients using anthropometric, biochemical and immunologic measures of nutritional status.
These surveys have indicated that SO-68% of patients with congestive heart failure were significantly malnourished3~. The proportion of malnourished heart failure patients has been found to be higher than that of patients with cancer, alcoholism or those with acute infection.
The cause of protein-energy malnutrition is due to both reduced intake and increased energy demands. Cardiac failure results in a cascade of metabolic effects such as tissue hypoxia, anorexia, hypermetabolism, weakness, dyspnea and hypomotility of the gastrointestinal tract all leading to poor nutrient intake. Anorexia can be aggravated by unpalatable restrictive diets or by converting enzyme inhibitors or by an excess of diuretics, opiates and digitalis. Characteristics of the disease process such as fatigue and early satiety have all been reported in congestive heart failure patients consuming self selected diets3z~33. These factors lead to compromised food and nutrient intake and subsequently contribute to the poor nutritional status of these cardiac patients.
In addition, patients with heart failure have been shown to have significantly increased resting metabolic rates3a,3s,36,3' possibly due to the increased work of breathing, fever, cytokines or elevated sympathetic nervous system outflow.
The RDA for the vitamins and related micronutrients recommended by federal nutrition authorities in Canada, the United States and Western Europe (e.g. The Canada Food Guide) are obtained through the analysis of deficiency data in otherwise healthy humans and animals.
We have found that with the advent of disease, or due to genetic predisposition, specific metabolic pathways in individual organs and the function of some of these systems alter the nutritional requirements causing conditioned deficiency of both macro-(protein including amino acids, carbohydrates and fats) and micronutrients (electrolytes, trace elements, vitamins and special nutrient substances). Certain pharmaceutical agents or treatment strategies also influence these requirements.
The above considerations indicate that for heart failure and in other conditions detailed below the nutrient intake is instrumental in determining the evolution of tissue damage -its amelioration or acceleration. RDA data, although suitable for a healthy population, are not necessarily appropriate for patients suffering from certain forms of illness or predisposed to sickness through genetic constitution. There is a need for a nutritional supplement that can be taken by persons suffering from illness or with a genetic predisposition to illness.
Musculoskeletal System.
Data given above have clearly demonstrated the relationship of protein deficiency and mitochondria) dysfunction in skeletal muscle. In addition several nutrient agents have been shown to improve skeletal muscle performance. These include creatine, carnitine and taurine.
Central Nervous System.
Mitochondria) dysfunction has been noted as an important factor in several neurodegnerative diseases'e. A central role for defective mitochondria) energy production, and the resulting increased levels of free radicals, in the pathogenesis of various neurodegenerative diseases is gaining increasing acceptance'9.
Immune System.
Immune dysfunction occurs with aging and there is growing evidence that reduced immunity is related to reduced mitochondria) dysfunction4~.
_g_ THE INTERACTING PATHWAYS RESPONSIBLE FOR MITOCHONDRIAL FUNCTION.
We have found that the critical path in these interactions is the flow of energy substrates into the mitochondria through carnitine, the transfer of electrons through the complexes via CoQlO, and the modulation of the calcium pump by taurine. We consider the constituents of this path, namely Carnitine, CoQ 10 and Taurine, to be the core constituents required to promote mitochondria) function. We have found that these compounds act together on this critical path to provide a synergistic effect.
The other constituents of the cascade given in Figure 1 aid the action of this core by modulating oxidative stress which results from external factors and mitochondria) dysfunction and in turn promotes further dysfunction.
Adequate energy production is essential not only for cellular function but also for long term cell survival. Cellular energy production from nutrients, especially fatty acids need the coordinated action of a number of co-factors. Three factors namely, carnitine (critical for the transport of long chain fatty acid substrate), coenzyme Q 10 (a key transducer for mitochondria) oxidative phosphorylation), and taurine (a key modulator of calcium accumulation ) are important in promoting normal cell energetics.
DETAILS OF ALTERED MITOCHONDRIAL ENERGETICS IN HEART FAILURE.
The data for mitochondria) energetic dysfunction has been clearly documented in heart failure and therefore the following details will focus on heart failure as a paradigm.
In heart failure deficiency of carnitine promotes accumulation of toxic long-chain fatty acids;
deficiency of CoQ 10 alters electron transport and mitochondria) calcium accumulation also occurs, which can be corrected by the action of taurine. From Figure 1 it can be seen that normalization of any one of the above three constituents alone will not be sufficient to significantly benefit myocardial energy production in the presence of abnormalities the other factors in the myocardial bioenergetic pathway. In addition, from Figure 1, it can also be seen that the added action of creatine, known to be deficient in cardiac failure and antioxidants to reduce oxidative stress, known to be elevated in cardiac failure, will enhance the action of the three core constituents carnitine, CoQ 10 and taurine. For these constituents to be effective in remodelling the heart, the addition of protein is essential in any supplement.
These substances can be given as oral replacements to benefit both myocyte function and long-term survival.
Details of the deficiencies and altered metabolism of these constituents in cardiac failure and other diseases are given below. However, it has become apparent that this paradigm applies to a number of other diseases; these will be briefly discussed in each section where appropriate.
REGULATING INTRACELLULAR CALCIUM
The failing myocardium exhibits an increase in calcium content and impaired movement of intracellular calcium. Impaired uptake of calcium adversely affects diastolic relaxation whereas the kinetics of transsarcolemmal calcium flux and calcium release by the sarcoplasmic reticulum is a principal determinant of systolic function. Chronic intracellular calcium overload ultimately leads to cell death.
Taurine:
Metabolism and Physiological Role of Myocardial Taurine.
Taurine (2-aminoethanesulfonic acid) is a unique amino acid, which lacks a carboxyl group, and as such it does not enter into protein synthesis. Taurine appears to be an important amino acid for the modulation of cellular calcium levels, exhibiting a remarkable biphasic action by increasing or decreasing calcium levels appropriate to the maintenance of cellular calcium homeostasis4'.az,a3, In the heart, taurine appears to do this by affecting several myocardial membrane systems4'.4z,a3. It is reported to enhance Ca++-induced Ca++ release from the sarcoplasmic reticulum both directly and through inhibition of the enzyme phospholipid methyl transferase, influencing the phospholipid environment of the ryanodine-sensitive calcium channel. It also modulates cardiac Ca++ and Na+ through the cardiac sarcolemmal Na+-Ca++
exchanger and a taurine/sodium exchanger. Taurine also has antioxidant properties and reacts with a variety of potentially toxic intracellular aldehydes including acetaldehyde and malonyldialdehyde44,as Taurine is found in particularly high concentrations in the heart (15 -25mmole/g protein) representing approximately 60% of the free amino acid pool4'.a6. plasma levels are approximately 50 - 80mmo1/L. Taurine is not an essential amino acid in humans as it can be synthesized from cysteine or methionine46; however, most taurine in humans is obtained directly through dietary sources, particularly from fish and milk. Biosynthetic capacity is maturation dependent, being almost non-existent in the human fetus and newborn and progressively increasing until adulthood",48. Taurine uptake by the myocyte is an active process and b-amino acids such as beta-alanine share the transport site; it is saturable at taurine concentrations of 200 mmOle46,a8. In the heart the transport of taurine, like that of carnitine, can be stimulated by beta-adrenergic agonists or dibutyryl-c-AMP; however, in other tissues the c-GMP
pathways seem to be important~b. The taurine transporter of all tissues is regulated by the activation of two calcium sensitive enzymes: protein kinase C (which inhibits the transporter) or calmodulin (which stimulates transport)°8. This reciprocal regulation of intracellular taurine levels by these two enzymes is consistent with a physiologic role for taurine in the maintenance of intracellular calcium homeostasis.
The observation that TNF-a levels49 and soluble TNF receptors5o,s' are raised in heart failure suggest increased cytokine activity in this condition. Grimblesz has shown that the requirement for sulfur containing amino acids is increased when TNF-a is infused. Of greater significance is the fact that transsulfuration of dietary methionine to cysteine is reduced and in consequence levels of taurine and lung glutathione fall unless the animals are supplemented with cysteine.
These findings suggest that with increased cytokine activity as observed by uss' in severe heart failure, the need for cysteine and taurine will increase. Since cysteine will replenish not only taurine but also glutathione (an important endogenous antioxidant -see 'Oxidative Stress' section, below), it may be an important supplement for replenishing both.
Taurine Levels and Taurine Supplementation in Heart Failure.
Cardiac taurine concentrations are altered in heart disease. Cats have very little taurine biosynthetic capacity and may exhibit a taurine deficient cardiomyopathys3.
Prolonged taurine depletion of the myocardium has been shown to decrease contractile force through reduction of myofibrilss'. This finding is of interest because increased calcium levels in the myocyte can activate calcium dependant proteinases that in turn can lead to the breakdown and loss of myofibils54. Taurine depletion also renders the heart more susceptible to ischemic injury55. In this context it should be noted that myocardial taurine depletion has been reported following acute ischemic injurysb and cardiovascular bypass surgerys' In species other than the cat, myocardial hypertrophy and failure is associated with an increase in cardiac taurine concentration4'~58. In spite of this increase, orally administered taurine has been shown to have a cAMP-independent positive inotropic effect in animal models of left ventricular dysfunction'. Taurine administration has been shown significantly reduce calcium overload and myocardial damage in a variety of heart failure models including that induced by the calcium paradox, doxorubicin or isoproterenol or in hamster cardiomyopathy4'°s9,bo,6',62; it also has been reported to increase the survival of rabbits with aortic regurgitation63.
Taurine may have a beneficial effect on cardiac arrhythmiasb' including those associated with digitalis or catecholamine excessbs. Studies of taurine administration in humans have been limited. However, in patients suffering from congestive heart failure taurine, given in an oral dose of 1 gram three times per day, has been reported to be extremely well tolerated and to improve both hemodynamic state and functional capacity4',66.67 Taurine also appears to function as an osmoregulator and neuromodulator in the brain6g. In addition there is evidence that taurine modulates calcium influx and efflux in the brain, increases resistance to hypoxia and reduces seizure activity when administered intraperitoneally. In streptozotocin-induced diabetic rats taurine also appears to protect against the development of renal dysfunction45; cardiac studies have not been performed in this model. On the same lines taurine also protects the kidney and liver against doxorubicin (adriamycin) toxicityb9.
MYOCARDIAL ENERGETICS
L-Carnitine:
Carnitine in Health and Disease:
L-carnitine, an amino acid derivative (3-hydroxy-4-N-trimethylaminobutyric acid), plays a critical role in this bioenergetic pathway as it is essential for the transport of long-chain fatty acids from the cytoplasm into the sites of beta-oxidation within the mitochondria) matrix.'° The importance of carnitine has been recognized by the observation that carnitine deficiency occurs in several genetically determined metabolic abnormalities">'z where it is associated with the development of cardiomyopathy and skeletal muscle dysfunction. L-carnitine administration to these patients restored to a great extent cardiac and skeletal muscle function.
Evaluation of carnitine metabolism in several cardiac pathologies has led to the realization that carnitine deficiency may also be acquired and organ selective, a finding of great significance because fatty acid oxidation is a major source of energy for the myocardium.
The impaired heart, regardless of the etiology of the dysfunction (including ischemic or non-ischemic dilated cardiomyopathy, coronary, hypertensive, diabetic and valvular heart disease), exhibits a marked depletion (up to 50%) of myocardial carnitine levels (particularly free carnitine) in both animal models and man'3>'4,'s, with evolution of the heart disease. On the other hand, despite low cardiac levels, plasma carnitine levels increase'6. This finding makes plasma levels unrepresentative of the levels in the heart.
In addition to promoting the entry of fat into the mitochondria, carnitine binds acyl groups and releases free CoA. These processes benefit the myocyte in two ways, first it removes toxic short chain acyl groups and second maintains sufficient amounts of free CoA for mitochondria) function.
An example of the detoxifying action of carnitine is seen in the ischemic myocardium"~'g. In ischemic myocardium or skeletal muscle there is an accumulation of long chain acyl-CoA; these compounds are potentially toxic as they exhibit both detergent-like properties and can impair mitochondria) energy production through the inhibition of a mitochondria) membrane enzyme, adenine nucleotide translocase, which transfers newly synthesized ATP from the inner mitochondria space into the cytoplasm. Carnitine protects the heart (or skeletal muscle) from the accumulation of these metabolic poisons by forming acylcarnitines, which can freely diffuse out of the cell and be eliminated through the urine.
Carnitine deficiency has also been observed in patients with chronic renal failure; an improvement in cardiac function following carnitine therapy has been reported for those on hemodialysis'9.
Carnitine Supplementation and Treatment:
Body stores of 1-carnitine are supplied by both diet and via endogenous biosynthesis from trimethyllysine. The concentration of carnitine in normal adult cardiac and skeletal muscle is approximately 8 - I S nmol/mg non-collagen protein; plasma levels are approximately 35 - 50 mmol/L. Thus plasma levels are generally not good measures of tissue concentrations. Under normal conditions approximately 80% of carnitine is free and the remainder complexed as fatty acylcarnitine. A 20-SO:I intracellular to extracellular carnitine gradient is maintained by a sodium-dependent plasma membrane transport system. Carnitine transport can be stimulated by beta-adrenergic agonists or dibutyryl-cAMP.
Following oral administration, peak plasma concentration occurs at 3 hours and decays with a T"Z of 3 - 4 hours; the turnover of endogenous cardiac or skeletal muscle carnitine is likely on the order of several days. The bioavailability of I-carnitine is limited to approximately 5 - 20%
probably due to clearance by the liver. L- carnitine is well tolerated and no adverse effects have been described.
Acetyl-1-carnitine and proprionyl-1-carnitine are naturally occurnng derivatives of 1-carnitineg°.
Acetyl-1-carnitine has been shown to influence mitochondria) DNA synthesis, is depleted by antiretroviral drugs and is non-toxic when infused intravenouslyg'. The administration of acetyl-I- carnitine has been shown to effectively replace decreased carnitine stores in the brain and heart associated with aging in rats82. Acetyl-1-carnitine has excellent penetration of the CSF and is likely to be of benefit in neurodegenerative conditions such as Alzheimer's diseaseg'~g3. Acetyl-I-carnitine has also been shown to be of benefit to peripheral nerve function in experimental diabetes8°.
Proprionyl-1-carnitine has also been used for cardiac therapy85~86~8'~88.
Proprionyl-1-carnitine directly penetrates the cell membrane and has a high affinity for the protein carriers; within the mitochondria the enzyme carnitine acetyl transferase releases 1-carnitine and proprionyl-CoA and the latter is transformed into succinyl CoA which can prime the citric acid cycle and the production of ATP89~9o. The proprionyl group appears to stimulate fatty acid oxidation (whereas the acetyl group inhibits this)$'.
L-carnitine (3 - 5 grams) or proprionyl-1-carnitine (1.5 - 3.0 grams) administration has been shown to result in significant hemodynamic improvement and an overall benefit in the functional capacity of animals and patients with heart failure or myocardial lSChemla'2''3,79,85,86"91,92.93,94,95,96,97,98,, Clinical studies report a reduction in cardiac damage, when I-carnitine is taken from 4 - 12 weeks following myocardial infarction'g~92. It also appears to benefit patients who suffer from skeletal muscle ischemia manifested as intermittent claudication. Circulating levels of tumour necrosis factor, a cytokine that leads to muscle wasting and cardiac dysfunction, correlates with functional class and prognosis of patients with heart failures'; in this context it is of interest that proprionyl-1-carnitine administration tends to normalize the circulating levels of this cytokine in patients with heart failure98.
Ubiquinone or Coenzyme Q10:
CoenTjymeQlO in Health and Disease'°"'°""°a.°
99).
Coenzyme Q 10 or ubiquinone (2,3 dimethoxy-5 methyl-6-decaprenyl benzoquinone) plays a vital role as a rate-limiting carrier for the flow of electrons through complexes I, II and III of the mitochondria) respiratory chain. It is also a major endogenous lipophilic antioxidant and, like vitamin C, can regenerate a-tocopherol, the active form of vitamin E by reducing the a-tocopherol radical. A deficiency of ubiquinone caused by actual loss or through oxidation of the molecule can result in an impairment of energy production. The molecule is sited within the inner mitochondria) membrane but is also associated with the membranes of other intracellular organelles. It is also an important component of circulating LDL particles, protecting LDL from oxidation.
Ubiquinone is actively biosynthesized with the cells. The quinone ring is synthesized from the amino acid tyrosine and the polyisoprenoid side chain is formed through the acetyl CoA -mevalonate pathway. The latter pathway is under the control of the enzyme hydroxy-methylglutaryl coenzyme A reductase (HMGCoA reductase) and is also used for cholesterol synthesis; inhibition of this pathway using HMGCoA reductase inhibitors, drugs which decrease -1~-plasma cholesterol, also results in a parallel decrease in plasma ubiquinone'°° and may also reduce tissue ubiquinone levels'°' Significantly reduced levels of myocardial ubiquinone are found in heart failure in both animal models and man'°2,'o3.~oa, Since the heart depends upon aerobic oxidation for its energy needs, ubiquinone, which is critically necessary for oxidative energy production is very important for cardiac function. The antioxidant properties of ubiquinone would add to this benefit.
Ubiguinone Sunnlementation and Treatment ,99,105,106,107 Ubiquinone is widespread throughout all food groups and thus body stores may also be partially supplied by diet. The concentration of ubiquinone in normal cardiac muscle is approximately 0.4 - 0.5 mg/mg dry weight, slightly less in skeletal muscle and 0.6 - l.3mg/ml in plasma. Oral absorption is slow and markedly enhanced in the presence of lipid; plasma levels peak at 5 -10 hours and decay with a T"~ of 34 hours. There is a large hepatic first pass effect so that only about 2 - 5 % of an oral dose is taken up by the myocardium. The mean steady state level in plasma increases 4 - 7 fold after 4 days of dosing at 100 mg 3 times daily.
Side effects are virtually absent; however, asymptomatic elevations in liver enzymes (LDH, SGOT) have been described with doses of 300 mg/day.
Oral ubiquinone therapy has been shown to result to beneficially affect cardiac dysfunction in a variety of animal paradigms'°g~'o9,"0. Oral ubiquinone also has been reported to reduce the age-associated decline in mitochondria) respiratory function in rat skeletal muscle"'. The controlled trials in patients with heart failure show clinical benefit, reducing symptoms, lessening hospitalization and improving myocardial performance99°'o2.~o3,~os,.az>a3.aaa~s.
Creatine:
Role of Creative in Health and Disease.
Creative phosphate (PCr) is the primary high-energy phosphate reservoir of the heart and skeletal muscle. High-energy phosphate is transferred from PCr to ADP to form ATP
through catalysis by creative kinase"6:
PCr + ADp + H+ <__> ATP + Cr Muscle creative stores are maintained through biosynthesis from endogenous precursors arginine, glycine, and methionine in the liver, pancreas and kidneys, and through the ingestion of meat and fish. The concentration of total creative in normal adult human myocardium or skeletal muscle is approximately 140 mmol/g protein; creative phosphate constitutes about 65 - 80% of the total creative under aerobic conditions"6. Creative is accumulated by muscle against a large concentration gradient from the blood; the transporter is probably driven by the extracellular/intracellular Na+ electrochemical potential"6°"'. Tr~ere is evidence that increased adrenergic drive (a characteristic of heart failure) can decrease myocardial creative and creative kinase stores'zs, ~za, Experimental creative depletion in animals results in structural, metabolic and functional abnormalities in muscle"'. Myocardial creative content and myocardial energetics is reduced in a wide variety of animal paradigms of heart fallure'16,118,119.123,120. No data is available regarding creative replacement in these models. However creative has been shown to attenuate myocardial metabolic stress in rats caused by inhibition of nitric oxide synthesis'z' Hearts from patients with coronary artery disease, aortic stenosis or heart failure all show a marked reduction in total creative (up to SO%) with an expected concomitant reduction in creatine phosphate'zzaz3; creatine kinase is also reduced"6~"'. These reductions interact synergistically decreasing myocardial capacity for ATP synthesis by up to 80%"6~' ~'~'za. Such an energy deficit has a significantly adverse impact on myocardial function and survival. Similar abnormalities of energy stores and production are seen in the skeletal muscles of patients of heart failure; these play an important role in compromising the functional capacity of these patients'zs.
Recently, it has been reported that the myocardial PCr/ ATP ratio may be a better predictor of patient mortality in dilated cardiomyopathy than left ventricular ejection fraction or the patient's functional class'zb.
Creatine Supplementation and Treatment.
The role of creatine supplementation may not be observed in normal cardiac or skeletal muscle under normal levels of performance. However, supplementation has been shown to increase performance in situations where the availability of creatine phosphate is important'z'aza, Ingestion of 3 g of creatine per day for one month (or 20 g per day for one week) increases muscle creatine content and can improve performance'z9. Daily turnover of creatine to creatinine for a 70 kg male has been estimated to be approximately 2 g99. Creatine supplements will increase skeletal muscle creatine and increase muscle resistance to fatigue during short-term intense exercise where it reduces lactate accumulation'3o,'3','3z. It also appears to be of benefit when given in adequate doses to patients with heart failure where myocardial and perhaps skeletal muscle creatine and creatine phosphate levels are depressed. The administration of a creatine supplement to patients with heart failure did not increase cardiac ejection fraction but significantly increased not only skeletal muscle creatine phosphate but also muscle strength and endurance'33 and thus would benefit patient symptom-limited performance.
Thiamine:
Thiamine or vitamin B, status may be compromised in heart failure due to a variety of causes.
Thiamine is a water-soluble vitamin which functions as a coenzyme in a variety of enzyme systems especially those related to energy metabolism. Thiamine is stored in very small quantities (approximately 30 mg) with approximately half of the body stores being found in skeletal muscle with the remainder being found in the heart, kidney and nervous tissue including the brain. Since little is stored, thiamine requirements must be met daily.
Thiamine requirements are related to daily energy expenditure'3a and metabolizable energy intake, especially carbohydrate intake and therefore patients with increased metabolic rates or poor intakes, such as those with heart failure, may be at increased risk for deficiency during acute illness'3a,'3s. T'he Food and Nutrition Board, USA recommends that for adults with energy intakes below 2000 kcal/day that a basal requirement of 1.0 mg thiamine per day be maintained'36. The Canadian recommendations support an intake of 0.4 mg/1000 kcal or no less than 0.8 mg/day for adults'3'. Thiamine intake in patients with heart disease has been examined in only one study using a semi-quantitative food frequency questionnaire focusing on foods high in thiamine'38. Nutrient analysis indicated a low overall intake of thiamine of 0.966 mg/day with 33% of patients not meeting the Recommended Dietary Allowance (RDA) for thiaminebs. This study also indicated that thiamine-deficient diets were more common among patients treated as out-patients rather than in-patients.
Necropsy studies indicate that thiamine deficiency is underdiagnosed in life'35. Classical deficiency signs are often absent or they are not recognized'39. Thiamine deficiency results in beri beri, which can have neurological or cardiac effects. The symptoms that are most common are mental confusion, anorexia, muscle weakness ataxia, edema, muscle wasting, tachycardia and an enlarged heart'4°. Thiamine deficiency leads to several major derangements of the cardiovascular system including peripheral dilatation leading to a high output state, biventricular myocardial failure, retention of sodium and water leading to edema as well as a relative depression of left ventricular function with low ejection fraction'4°'"'. This picture will be masked in preexisting low-output heart failure. Since thiamine deficiency will exacerbate co-existing heart failure, correction of this deficiency through supplementation has the potential to improve cardiac status in patients with congestive heart failure.
In addition to poor dietary intake and increased metabolic utilization, referred to above, patients with heart failure also may be at risk for thiamine deficiency because of their need for diuretics.
There is evidence from both animal and human studies that diuretics, especially those which affect the Loop of Henle such as furosemide, cause increased urinary losses of thiamine even in the presence of thiamine deficiency'42,'a3. It appears that furosemide treatment may block the kidneys' ability to adapt thiamine excretion in order to prevent thiamine deficiency. These data demonstrate that patients with heart failure are at increased risk of thiamine deficiency due to a combination of 1 ) poor intake resulting from anorexia and unpalatable diets, 2) hypermetabolism, and 3) enhanced excretion caused by the concurrent use of diuretics.
There have been a handful of studies which support a high prevalence of thiamine deficiency in both in- and outpatients with congestive heart failure - from 13% to 91%
depending on the population studied'3g~'a3,~aa,~as, A very high (91%) prevalence of thiamine deficiency has been reported in a group of congestive heart patients on long-term furosemide treatment'a3. The average dose of furosemide ranged from 80-240 mg/day. Biochemically, the furosemide-treated group had severe thiamine deficiency indicating that doses of this magnitude have significant effects on thiamine status. These investigators undertook a randomized double-blind trial of thiamine supplementation in 30 in-patients with heart failure and on long-term furosemide therapy'46. Patients were randomized to receive 200 mg intravenous thiamine or a placebo for seven days after which all subjects were placed on an oral supplement of 200 mg/day of thiamine and followed for an additional six weeks. They saw a significant diuresis with increased excretion of sodium and water within two days of thiamine supplementation in comparison with the placebo group whose excretion remained constant. The mean left ventricular ejection fraction increased significantly after one week of thiamine supplementation but not with the placebo. After six weeks of oral thiamine supplementation left ventricular ejection fraction was increased by 22%. This study demonstrates a significant improvement in left ventricular function as a result of thiamine supplementation in patients with CHF. In addition, improvement in left ventricular function was accompanied by diuresis and increased sodium excretion, which is hypothesized to be one of the major effects of thiamine supplementation.
Finally, it should also be noted that thiamine deficiency is also commonly present in patients on hemodialysis'4', in patients in intensive care units'48 and perhaps cognitive impairment in the aged' 49.
REDUCING OXIDATIVE STRESS
Cells are constantly subjected to interplay between free radical injury and protective mechanisms to prevent or minimize free radical injury. Oxidative stress has been defined as a disturbance in the equilibrium between pro- and anti-oxidative systems. A number of different challenges increase oxidative stress resulting in damage to lipids, proteins, DNA and carbohydrates.
Dietary Antioxidants - Vitamin E, Vitamin C, Cysteine and Selenium -counteract the effect of free radicals generated by external factors and by mitochondria) dysfunction.
Cysteine is the precursor of glutathione, one of the most potent antioxidants present in the cell.
Role of Oxidative Stress in Cardiac Disease.
Until recently there has been a reluctance to accept that oxidative stress can be important in the pathogenesis of cardiac disease however, recent investigation suggests that oxidative stress may be a very important contributor to the deterioration of the hypertrophied or failing myocardium.
For example, reactive oxygen species have been shown to be critical components of the apoptosis pathway's°; myocyte loss by apoptosis is now thought to be a significant contributor to the inexorable deterioration of the failing myocardium's'. The importance of oxidative stress in heart failure is not surprising because a number of factors associated with heart failure, such as increased plasma catecholamines,'sz and cardiac sympathetic tone's3, microvascular reperfusion injury'sa>>ss cytokine stimulation49~so and mitochondria) DNA mutations (particularly complex I)'sb are known stimuli for free radical production and oxidative stress's'~'ss,~s9,~6o. Coenzyme Q10 and taurine (and its precursor cysteine), discussed above are important endogenous antioxidants or antioxidant precursors.
Peroxidative damage has been demonstrated in the hearts of dogs, guinea pigs and rats with heart failure due to pressure or volume overload'6'.'62,'63. Vitamin E
administration benefited'' both myocardial structure and function. We have observed decreases in the levels of glutathione peroxidase and a-tocopherol and a concomitant increase in protein oxidation in the myocardium of cardiomyopathic hamsters during the late stages of hamster cardiomyopathy'bs ; an elevation of myocardial free radicals and lipid peroxides have also been demonstrated in this model'66. The administration of vitamin E appears to completely normalize these findings'63.
Recently, we have also demonstrated a significant increase in the plasma level of lipid peroxides and malonyldialdehyde, markers of oxidative stress, in patients suffering from congestive heart failures'. The increase in oxidative stress was related to the clinical severity of heart failure with the highest levels of lipid peroxidation and malonyldialdehyde being observed in class 3 and class 4 patients. Increased free radical activity is also seen in patients on life support or in intensive care unit settings'6'. These observations suggest that antioxidant supplements should be important additions to the therapy of heart failure and severely ill patients.
The ability to withstand peroxidative injury is partially dependent on diet. A
good dietary intake of the antioxidant vitamins C and E, and trace nutrient minerals such as selenium together with adequate cysteine as a precursor for glutathione synthesis are important for protection against free radical injury. Fat intake and composition is also important, the need for vitamin E may be increased by an increased intake of polyunsaturated fatty acids'6s. It has been suggested that the vitamin E requirement = 5.96 + 0.25 (% PUFA kcal + g PUFAs). With the North American diet increasing in PUFA, Diplock has suggested that the current RDA (recommended daily allowances) be increased fourfold'69. Dietary antioxidants may reduce the risk of ischemic heart disease and the extent of myocardial infarction"°'"'°"z. Recent reports suggest an increased need for vitamin C in patients with diabetes mellitus"3. Finally oxidative stress is also felt to be a major contributor to chronic neurodegenerative disease and the tissue deterioration and immune dysfunction associated with aging"'' "s, »6, "', as, X79, ~so, ~s~, ~sz, ~s3,~sa.
Correction of Mitochondria) Abnormalities.
Other investigators have used certain of these nutrients alone. We have found that a preferred nutritional supplement would replace the constituents given above and influence several metabolic pathways interacting to subserve mitochondria) function. We have found that replacing only one of the core constituents will not correct the connected abnormalities in multiple parts of the myocardial bioenergetic pathway which is deranged in cardiac failure.
Rather, our supplement helps to correct the cascading series of metabolic abnormalities in patients with myocardial dysfunction and other diseases mentioned above, rather than merely a problem at a single point in a pathway.
In a preferred embodiment, the invention relates to a method of medical treatment of a disease, disorder or abnormal physical state in a mammal selected from the group consisting of heart disease and functional deterioration associated with ageing, the method comprising administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or its precursors in a single or divided daily dose.
In one variation, the method includes administering to a mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine, Coenzyme Q10 (Ubiquinone) and Taurine or its precursors in a single or divided daily dose. The mammal is preferably one of the group including humans, dogs, cats and horses. The disease, disorder or abnormal physical state may include a disease, disorder or abnormal physical state that is due in whole or in part to aging.
Another variation of the invention includes a method of increasing neuromuscular or muscular or athletic performance in a mammal, the method including administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue and Taurine or its precursors in a single or divided daily dose. Another aspect of the method includes administering to the mammal an effective amount of a carrier and a nutritional supplement comprising L-Camitine, Coenzyme Q10 (Ubiquinone) and Taurine or its precursors in a single or divided daily dose. The mammal is preferably one of the group including humans, dogs, cats and horses. The method and composition improves functional performance and muscular performance. In one embodiment, for an 80 kg man, suitable amounts would include at least about 2.7g taurine, at least about 2.7g L-carnitine and at least about 135 mg of CoQlO.
BRIEF DESCRIPTION OF THE DRAWINGS.
Figure 1 is a schematic diagram of the interaction of the nutrients included in this invention and their interaction in cell energetics.
Figure 2 shows electron micrographs of heart specimens from hamsters in Experiment 1. (a) control non-treated heart (b) cocktail treated heart (c) normal hamster heart.
Figure 3 shows the mean pressure of contraction of hamster hearts (Langendorff Model) in Experiment 1. (a) normal hamster heart (b) control non-treated heart (c) control non treated heart (d) control non-treated heart and cocktail treated heart (e) cocktail treated heart (f) cocktail treated heart.
Figure 4 shows plasma vitamin E levels as a measure of compliance.
Figure 5 shows that exercise capacity at 12 weeks with the supplement increased by approximately 30%.
Figure 6 (a) shows a preferred embodiment of a supplement of the invention.
One packet includes about 125 mL of solution. About 250 mL is the recommended daily dose for a human (preferably for a male of about 80kg). Variations of this embodiment may be made. For example, many of the compounds indicated in brackets on the chart may be varied, such as to use forms of Vitamin C other than the specific form indicated in brackets. Masses used in variations are preferably at least about those masses listed in the chart. As well, specific changes include using at least about 67.Smg of Coenzyme Q10, at least about 1.35g of L-carnitine , at least about 875 mg of creatine and at least about 1.35 g of taurine per pack. Each pack includes about 125mL of solution (carrier). These amounts are preferably given at 250mL daily in a single or divided daily dose. (b) shows a variation of the supplement. Amounts greater or less than than the masses (including ranges, where shown) shown in figures 6(a) and (b) may be administered depending on individual need. In another variation of the supplement of the invention, carnitine, taurine, and coenzyme Q 10 may be administered alone.
DETAILED DESCRIPTION OF THE INVENTION
Researchers have not recognized that optimizing mitochondrial function depends upon the synergistic correction of cellular and mitochondrial energy substrates (Figure 1 ) which will lead to improved energetics, reduced oxidative stress and better calcium homeostasis, a synergistic response clinically beneficial to the patient.
The conventional approach has been to try single nutrients. This has led to conflicting results, at best.
The combination of nutrients of this invention addresses what we have found to be an interrelated series of disruptions in cellular metabolism, that are present in heart failure and conditions such as aging, chronic neurodegenerative disease, immune diseases such as AIDS, chronic multisystem disease, chronic lung or renal disease, chronic fatigue syndrome, patients on immunosuppressive drugs post-transplantation, cancer patients on doxorubicin or related drugs, wasting or cachexia from cancer or sepsis and in normal humans wishing better neuromuscular or athletic performance, and thus provides more reliable, effective treatment.
The combination is preferably delivered orally, but other methods of administration such as intravenous administration may be used.
The invention is a nutritional supplement that helps to correct or prevent the cascading series of metabolic abnormalities responsible principally for cardiac disease but will have a similar effect on neuromuscular, central nervous and immune system dysfunction in a wide variety of diseases.
Rather than merely addressing problems at particular points in metabolic pathways, the nutritional supplement of the invention uses a holistic approach to restoring and improving function at many points in cell metabolism, for example at multiple points along the mitochondria) bioenergetic pathway. The effectiveness of this nutritional supplement in preventing and correcting myocardial dysfunction has been demonstrated in vivo (Example 1 ).
This invention relates to a dietary supplement comprising effective amounts of L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-1-Carnitine), Coenzyme Q 10 (Ubiquinone or its functional analogues) and Taurine as the minimal number of core constituents essential for the correction of the abnormality in mitochondria) energetics in cardiac failure and the different diseases referred to above. Additional supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopheryl), Vitamin C (ascorbic acid), Selenium, and Thiamin in a high protein nutritional feeding are preferred.
This invention relates to a dietary supplement taken in a high protein formulation such as a dairy based drink, a dehydrated dairy product, Soya based drink or dehydrated product, or a nutritional bar which may contain: L-Carnitine 0.5-5 g or its functional analogues such as Acetyl- and Proprionyl-1-Carnitine 3 g, Coenzyme Q10 (Ubiquinone) 30-200 mg (preferably at least about 150 mg) or its functional analogues, Taurine 0.1-3 g. Addition of Cysteine O.Sgm-1.5 g, Creatine 2.5 g, Vitamin E (RRR-d-alpha-tocopheryl) 600 IU, Vitamin C (ascorbic acid) 1000 mg, Selenium 50 mcg, Thiamine 25 mg will aid the action of the core constituents.
These doses may vary 25% to 300% for specialized formulations. Coenzyme Q10 (Ubiquinone) preferably is at least about 1 SO mg.
This formulation ensures a high quality protein to optimize muscle function so as to allow the above nutrients in combination to synergistically interact for the benefit of the patient - that is the effect of all of the ingredients combined will be greater than the sum of the individual parts as they address a cascading series of metabolic abnormalities. There is a core of specific nutrients, which must be combined to be effective, and a larger number for optimal effectiveness.
Conversely omission of the core will detract from the overall efficacy of this supplement. In addition to maintaining protein stores, the supplement corrects abnormalities in: (a) myocardial energetics, (b) intracellular calcium and (c) oxidative stress.
This supplement also benefits patients, with or without heart failure, with other conditions in which cellular nutrition, mitochondrial energetics and function are impaired or less than desired and oxidative stress is increased, including but not exclusively for musculoskeletal, immune and disorders of the central nervous system especially those related to aging.
Such disorders include neurodegenerative disease, immune diseases, stroke, AIDS, chronic multisystem disease, respiratory muscle fatigue such as chronic obstructive lung disease, lung or renal disease, chronic fatigue syndrome, patients on immunosuppressive drugs, cancer patients treated with drugs such as doxorubicin, wasting, cachexia from cancer or sepsis Effectiveness of Nutrient Cocktail In Vivo:
In vivo data gained from cardiomyopathic hamsters showed the synergistic effect of the nutritional supplement (Experiment 1 ). It also showed the feasibility of providing a cocktail of nutrients to cardiomyopathic hamsters and that the mixture positively affected cardiac structure, function and markers of oxidative stress, deterioration of mitochondrial and myofibrillar structures in non-treated animals with improved preservation in treated animals. The results show that there are increased areas of necrosis in non-treated hearts in comparison with treated hearts. These results show that this cocktail of nutrients is effective in preserving myocyte function and structure.
Example 1 - Cardiac Nutrient Cocktail Study We performed a pilot study in order to determine the feasibility of providing a "cocktail" of nutrients as well as their effect on indices of oxidative stress as well as on myocardial structure and function.
Composition of Cardiac Cocktail L-carnitine 300 mg/kg/day V itamin E 147 mg/kg/day Vitamin C 100 mg/kg/day Coenzyme Q,o 15 mg/kg/day Thiamine (B,) 100 mg/kg Cysteine 12 mg/day Selenium 0.05 mg/day (S mglkg diet) Taurine 188 mg/day ( 18.8 g/L) Creatine 100 mg/day ( 1 % diet) Method of Delivery The nutrients were delivered in l Oml of raspberry Jell-O. Water soluble nutrients were added directly to the cooled Jell-O while lipid soluble components were mixed with 15 ml 20%
intralipid prior to their addition to the cocktail mixture.
Study Design 180-day old cardiomyopathic hamsters were started on supplementation after a two-week acclimation period. 18 animals received Jell-O supplemented with nutrients while 18 received the identical Jell-O but without nutrients. The animals received full supplementation for eight weeks, at this time the animals were 278 days of age. At this time, 6 treated, 6 untreated and 6 non-diseased hamsters underwent the Langendorff procedure modified for hamsters following which the hearts were preserved for electron microscopy. The remaining animals were sacrificed and blood, hearts, livers and muscle were collected for biochemistry.
Results a) Mortality - In the treated group, 2 hamsters died. Of the non-treated group, 4 hamsters died with an additional hamster being moribund at the time of study.
b) Appearance - The treated hamsters remained active and alert with no visible edema. In contrast, two of the non-treated animals became grossly edematous with exceptionally large black livers. The control non-treated animals were less active and appeared less bright.
c) Biochemistry - The heart and plasma were analysed for indices of oxidative stress.
Control - Non Cocktail Treated Treated Heart Glutathione Peroxidase 113.05 ~ 8.20 134.34 t 16.7 Activity Units/min/mg protein Heart Malondialydehyde ug/g 2.00 ~ 0.25 1.67 ~ 0.22 wet weight Plasma Malondialydehyde nmol/ml0.17 ~ 0.009 0.14 ~ 0.04 plasma Plasma Glutathione Peroxidase 5.24 ~ 0.82 6.03 t 0.51 Activity Units/min/mg protein Ratio Heart Weight: Body Weight0.008 t 0.0007 0.007 ~ 0.0006 D. Function Non-Treated Treated Normal Hamster * Mean Pressure - 20.84 + 5.97 44.17 t 4.55 92.50 ~ 11.99 Langendorff mmHg * See attached tracings (Figures 3(a)-(f)) d) Microscopy - Electron micrographs (Figures 2 (a)-c)) show deterioration of mitochondria) and myofibrillar structures in non-treated animals with markedly improved preservation in treated animals. In addition, there are increased areas of necrosis in non-treated hearts in comparison with treated hearts. The results achieved were superior to those projected from individual studies of the ingredients.
e) Recently we have completed another study with the supplement and confirmed all the above results and in addition have shown a complete restoration of systolic contractility as measured by +dP/dT and diastolic relaxation as measured by -dP/dT.
Conclusions Nutrients have been used, singly or in random combination to treat several conditions including heart disease. We by contrast have found that three defined key components, L-carnitine, coenzyme Q 10 and taurine, interact in a way which potentiates the action of each on cell function and energetics. Creatine, thiamine and antioxidants support the action of this core. In addition protein enrichment also aids the maintenance of mitochondria) energetics. We have demonstrated the validity of this claim by preventing the development of heart failure in a genetic animal model normally subject to the inexorable progression of heart failure culminating in death. Other studies using nutrients have not shown comparable benefit.
In another embodiment of the invention, the nutritional supplement is adapted in an amount effective for administration to humans for the purpose of enhancing muscular or athletic performance.
A randomized placebo-controlled safety and efficacy study of a liquid supplement, containing about: 2.7 grams of taurine, 2.7 grams of carnitine, 135 mg coenzyme Q10 plus antioxidant vitamins (vitamin E - 400IU, Vitamin C - 250 mg) and 1.75 grams of creatine per 250 milliliters was performed in 33 healthy untrained human volunteers. The supplement was given for 12 weeks at 125m1 twice daily.
There were 2 dropouts in the placebo group between weeks 4 and 12. There were no dropouts in the active supplement group. Exercise capacity, measured as time until exhaustion at 110% of individual V02 max, was assessed at baseline and at weeks 4 and 12. Figure 4 shows plasma vitamin E levels as a measure of compliance. Figure 5 shows the results where exercise capacity at 12 weeks with the supplement increased remarkably by about 30%.
The nutritional supplement of may be adapted (appropriate to body mass and metabolic rate) to be administered to humans and other mammals, such as dogs, cats and horses, in amounts effective for correcting diseases, conditions and infirmities described in this application, including those due to aging. They may also be adapted (appropriate to body mass and metabolic rate) to be administered to humans and other mammals to enhance muscular performance.
Mammals tend to have a high and variable metabolic rate. Their requirements per gram of tissue differs from humans. By way of example, a rat has about four times the metabolic rate of a human. The amounts to be administered will also vary with the age of the mammal. The appropriate amount to be administered will be apparent to one skilled in the art.
The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. All such modifications are intended to be included within the scope of the appended claims.
Claims (8)
1. The use of a nutritional supplement comprising an effective amount of L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue, and Taurine or a Taurine precursor, and a carrier in a single or divided daily dose to treat or prevent in a mammal a disease, disorder or abnormal physical state selected from the group consisting of heart disease and a functional deterioration associated with ageing.
2. The use of claim 1, wherein the nutritional supplement comprises an effective amount of L-Carnitine, Coenzyme Q10 (Ubiquinone), and Taurine or a Taurine precursor, and a carrier in a single or divided daily dose.
3. The use of claim 1, wherein the mammal is selected from the group consisting of humans, dogs, and cats.
4. The use of claim 1, wherein the disease, disorder or abnormal physical state comprises a disease, disorder or abnormal physical state that is due in whole or in part to aging.
5. The use of a nutritional supplement comprising an effective amount of L-Carnitine or its functional analogue, Coenzyme Q10 (Ubiquinone) or its functional analogue, and Taurine or a Taurine precursor, and a carrier in a single or divided daily dose to increase neuromuscular or athletic performance in a mammal.
6. The use of claim 5, wherein the nutritional supplement comprises an effective amount of L-Carnitine, Coenzyme Q10 (Ubiquinone), and Taurine or a Taurine precursor, and a carrier in a single or divided daily dose.
7. The use of claim 5, wherein the mammal is selected from the group consisting of humans, dogs, and cats.
8. The use of claim 7, wherein the mammal is a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002285490A CA2285490C (en) | 1999-10-07 | 1999-10-07 | Composition for improvement of cellular nutrition and mitochondrial energetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002285490A CA2285490C (en) | 1999-10-07 | 1999-10-07 | Composition for improvement of cellular nutrition and mitochondrial energetics |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2285490A1 CA2285490A1 (en) | 2001-04-07 |
CA2285490C true CA2285490C (en) | 2003-11-18 |
Family
ID=4164319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002285490A Expired - Lifetime CA2285490C (en) | 1999-10-07 | 1999-10-07 | Composition for improvement of cellular nutrition and mitochondrial energetics |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2285490C (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115710A1 (en) * | 2000-10-31 | 2002-08-22 | Zicker Steven Curtis | Composition and method |
US20020076470A1 (en) | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
US8669282B2 (en) | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
US8592479B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals |
DK1641352T3 (en) | 2003-07-07 | 2010-12-06 | Hills Pet Nutrition Inc | Compositions for improved oxidative status in cats |
EP1830883B1 (en) | 2004-12-29 | 2013-10-09 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
CA2615060C (en) | 2005-07-14 | 2016-06-21 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
-
1999
- 1999-10-07 CA CA002285490A patent/CA2285490C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2285490A1 (en) | 2001-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6232346B1 (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
US6080788A (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
CA2284738C (en) | Nutritional composition for improvements in cell energetics | |
US6479069B1 (en) | Nutritional supplement for increased energy and stamina | |
ES2201451T3 (en) | DIETETIC FOODS FOR DIABETICS. | |
Sole et al. | Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure | |
EP1087779B1 (en) | Compositions for increasing energy in vivo | |
US5977162A (en) | Therapeutic treatment for auditory function | |
US5571783A (en) | Composition and method for treating patients with hepatic disease | |
Guarnieri et al. | Carnitine metabolism in uremia | |
AU2002224848B2 (en) | Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition | |
US5240961A (en) | Method of treating reduced insulin-like growth factor and bone loss associated with aging | |
Sole et al. | Conditioned nutritional requirements: therapeutic relevance to heart failure | |
EP0405295B1 (en) | Improved nutritional formulation for the treatment of renal disease | |
US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
KR20010071467A (en) | Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects | |
CA2285490C (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
US6218420B1 (en) | Compositions based on aminoacids | |
AU2001270980B2 (en) | Food supplement with a slimming effect | |
US20200338153A1 (en) | Anaerobic antioxidant composition | |
RU2335927C2 (en) | Nutrient compositions enriched with leucine | |
KR100198159B1 (en) | Composition for diet | |
US20020077349A1 (en) | Method of treating age-related vision impairment | |
CA2678746C (en) | Composition useful for the treatment of type 2 diabetes | |
WO2003009840A1 (en) | Composition comprising at least one lipase inhibitor and carnitine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |